Analysis of heart rate variability on diabetic patients by Brázio, Bruno Guerreiro
  
     
Bruno Guerreiro Brázio 
  
 
 
 
 
Analysis of heart rate variability on diabetic patients 
 
 
 
 
 
 
 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIAS 
2017
  
Bruno Guerreiro Brázio 
  
 
 
 
Analysis of heart rate variability on diabetic patients 
 
Mestrado Integrado em Engenharia Eletrónica e Telecomunicações  
Trabalho efetuado sob a orientação de:  
Professora Doutora Maria da Graça Ruano 
 
 
 
 
 
 
 
FACULDADE DE CIÊNCIAS E TECNOLOGIAS 
2017
iii 
 
Analysis of heart rate variability on diabetic patients 
Declaração de Autoria 
 
 
Declaro ser o(a) autor(a) deste trabalho, que é original e inédito. Autores e trabalhos 
consultados estão devidamente citados no texto e constam da listagem de referências 
incluída.  
 
Assinatura do candidato:____________________________________________________ 
Bruno Guerreiro Brázio 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright Bruno Guerreiro Brázio 
 
A Universidade do Algarve tem o direito, perpétuo e sem limites geográficos, de arquivar e 
publicitar este trabalho através de exemplares impressos reproduzidos em papel ou de forma 
digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, de o divulgar 
através de repositórios científicos e de admitir a sua cópia e distribuição com objetivos 
educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e 
editor.  
iv 
 
ACKLOWLEDGEMENT 
Foremost, I would like to express my sincere gratitude to my advisor Prof.ª M. Graça 
Ruano for giving me the opportunity to develop this project, for the continuous support 
on this journey, her availability, motivation, enthusiasm and knowledge.  
I also would like to thank my family: my parents Joaquim and Lilia, for their efforts to 
providing me the best education possible, for supporting me through my academic course 
and for loving me no matter what, my grandfather Manuel which inspired me so much 
during my thesis and my girlfriend Marlene for the support, encouragement and helping 
me when I needed the most. 
I would like to also thank my colleagues who provided me great moments on this journey. 
Finally, I would like to thank the sponsorship of LINK - Linking Excellence in 
Biomedical knowledge and Computational Intelligence Research for Personalized 
Management of Cardiovascular Diseases within Personalized Health Care, 692023 
H2020, (2016-2019). 
 
 
  
v 
 
ABSTRACT 
Diabetes mellitus (DM) is a chronic condition in which the body produces insufficient 
insulin, or it cannot be used properly. This condition induces abnormal cardiovascular 
behaviour due to the irregular pattern of glucose levels in blood, being responsible for an 
increased morbidity within DM patients. So, researching non-invasive methods of early 
detection of cardiovascular pathologies is a valuable help for clinical diagnose.   
This work concentrates on the analysis of the electrocardiogram (ECG) of DM patients 
with different cardiac pathologies. The signal processing methodology adopted is to 
consider the ECG signal as a time-series. The identification of signals’ pattern for a 
specific pathology is searched by analysing the similarity between time-series 
representations of the same type of pathology and verifying the difference among 
differentiated pathologies. Searching for time-series similarity of non-stationary signals 
may be performed in time, frequency or transformed domains. Each of these similarity 
methods present pros and against which have to be evaluated within the cohorts 
considered in this study. 
A collection of seven similarity methods was assessed on their ability to find the similarity 
among each cohort, considering the ECG 12 conventional leads’ signals together with the 
3 Frank leads’ signals. The cohorts were composed of ECG signals available at the public 
database Physionet. Different cohorts were created considering groups of data related to 
patients with the same diagnosis (myocardial infarction, diabetes mellitus, renal 
insufficiency, hyperuricemia, arterial hypertension and healthy controls), gender and age 
range. The performance of the similarity measurement methods was evaluated by 
confronting the signal processing results with the clinical annotations contained in the 
database. 
Also, to broaden the comparison of the obtained results with other researchers who 
provide conclusions based on the heart rate variability (HRV), an analysis of this 
parameter will also be reported. 
Analysis of the results enabled identification of the best performed similarity method – 
which was Pearson’s correlation coefficient method, to use under specific illness 
constraints – diabetes mellitus and myocardial infarction, being obtained, in this case, a 
pattern with 73% similarity. Confronting the obtained results with the published ones 
vi 
 
enabled confirmation of the most reliable ECG leads (aVL, L1, V4 and VZ) to identify 
DM myocardial infarction. In what concerns de HRV analysis we concluded that CVD 
patients, in overall, have lower HRV in comparison with healthy individuals. 
Keywords: Diabetes mellitus, time-series, data mining, similarity measures, 
electrocardiogram (ECG), heart rate variability (HRV). 
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RESUMO 
Diabetes mellitus (DM) é uma condição crónica em que o corpo produz insulina 
insuficiente, ou a qual não pode ser usada corretamente. Esta condição induz o 
comportamento cardiovascular anormal devido ao padrão irregular de níveis de glicose 
no sangue, sendo responsável por uma maior morbidade nos pacientes com DM. Assim, 
a pesquisa de métodos não invasivos de deteção precoce de patologias cardiovasculares 
é uma valiosa ajuda para o diagnóstico clínico. 
Este trabalho concentra-se na análise do eletrocardiograma (ECG) de pacientes com DM 
com diferentes patologias cardíacas. A metodologia de processamento de sinal adotada 
consiste em considerar o sinal de ECG como uma série temporal. A identificação do 
padrão de sinais para uma patologia específica é pesquisada analisando a semelhança 
entre representações de séries temporais do mesmo tipo de patologia e verificando a 
diferença entre patologias diferenciadas. A procura de semelhanças em séries temporais 
de sinais não estacionários pode ser realizada nos domínios do tempo, frequência ou 
transformados. Cada um desses métodos de semelhança apresenta prós e contras, os quais 
devem ser avaliados dentro das coortes consideradas neste estudo. 
Uma coleção de sete métodos de similaridade foi testada e avaliada quanto à sua 
capacidade de encontrar a semelhança entre cada coorte, considerando os 12 sinais 
convencionais do ECG (i, ii, iii, avr, avl, avf, v1, v2, v3, v4, v5, v6) e ainda os sinais de 
3 sensores do tipo Frank (vx, vy, vz). As coortes foram compostas por sinais de ECG 
disponíveis no banco de dados público Physionet. Coortes diferentes foram criadas 
considerando grupos de dados relacionados a pacientes com o mesmo tipo de diagnóstico 
(infarto do miocárdio, diabetes mellitus, insuficiência renal, hiperuricemia, hipertensão 
arterial e controle de pessoas saudáveis), género e faixa etária. 
O desempenho dos métodos de medição de similaridade foi avaliado ao confrontar os 
resultados do processamento do sinal com as anotações clínicas contidas no banco de 
dados. 
Além disso, para ampliar a comparação dos resultados obtidos com a de outros 
investigadores que apresentam conclusões com base na variabilidade da frequência 
cardíaca, uma análise desse parâmetro também será relatada. 
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A análise dos resultados permitiu a identificação do método de semelhança com melhor 
desempenho - o método do coeficiente de correlação de Pearson, o qual deve ser usado 
mediante restrições específicas de doença, isto é, diabetes mellitus e infarto do miocárdio, 
sendo obtido, neste caso, um ciclo cardíaco padrão com 73% de similaridade aos casos 
analisados. Confrontados os resultados obtidos com os publicados permitiu a confirmação 
das derivações ECG mais confiáveis (aVL, L1, V4 e VZ) para a identificação do infarto 
do miocárdio em pacientes com DM. No que diz respeito à análise da variação da 
frequência cardíaca, concluímos que pessoas com doenças cardiovasculares têm menor 
variação do ritmo cardíaco em comparação com pessoas saudáveis. 
Palavras-chave: Diabetes mellitus, séries temporais, mineração de dados, medidas de 
semelhança, electrocardiograma, variação do ritmo cardíaco. 
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1. INTRODUCTION 
According to World Health Organisation (WHO) 
Diabetes mellitus is a chronic disease caused by inherited and/or 
acquired deficiency in production of insulin by the pancreas, or by the 
ineffectiveness of the insulin produced. Such a deficiency results in 
increased concentrations of glucose in the blood, which in turn damage 
many of the body's systems, in particular the blood vessels and nerves 
[1].  
Currently, WHO has published several recommendations on diagnostic values for blood 
glucose concentration (last modified in 1999), for a disease that causes suffering and 
hardship for approximately 60 million people in the European region for a total of 4422 
million all over the world [1, 2, 3]. 
There are many complications associated with diabetes mellitus [1], such as: 
1. Diabetic retinopathy which can lead to blindness and visual disability; 
2. Kidney failure, which in advanced stages obliges to haemodialysis; 
3. Heart disease, which develops at different types, being hypertension and coronary 
diseases the most frequent; 
4. Diabetic neuropathy can lead to sensory loss and damage to the limbs; 
5. Diabetic foot disease with subsequent limb amputation. 
In this work, we will concentrate on relating DM with point 3, this is, with heart 
diseases. We will also follow the line of previous investigations within the research 
group, that is to say that we will be considering the electrocardiogram (ECG) signals 
of patients, and processing them as time-series. Time-series are an important class of 
temporal data that arise from various sources, and to analyse the amount of data from 
those sets we need to use several data mining techniques. Working with this kind of 
data representation mostly means that issues such as non-constant sampling rate, 
noise, enormous amounts of data, etc may be overcome [4]. 
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Measuring similarity within time series plays an important role in finding a pattern, 
enabling prediction and knowledge discovery. In clinical context if we find a pattern of a 
specific pathology we can use that knowledge for disease prediction. That might mean 
allowing medical doctors with additional diagnosis support and therefore improving 
medical prescriptions, eventually decreasing the number of screening medical exams with 
their consequent economic savings, besides enabling better disease control with the 
correspondent social impact. 
As mentioned this work concentrates on DM cardiac pathologies ECG analysis. To find 
a pattern for DM different methods of similarity measures were considered on the 
conventional 12 leads (i, ii, iii, avr, avl, avf, v1, v2, v3, v4, v5, v6) together with the 3 
Frank leads (vx, vy, vz) ECG from different cohorts. Several time-series similarity 
measuring methods were tested, whose performance were evaluated by confronting the 
signal processing results with the clinical annotations. 
Analysis of the results enables not only the identification of the ECG leads which are 
more representative of the classes of pathologies under consideration, but also 
identification of the best similarity measures for this kind of experiments. 
Many authors analyse CVD through heart rate variability (HRV). It will also be addressed 
the evaluation of this clinical parameter. 
The structure of this thesis is organized into five chapter. 
The present chapter presents a general introduction of this thesis.   
Chapter 2 describes some fundamental concepts for the understanding of the upcoming 
chapters. Such as interpreting an electrocardiogram, what heart rate variability represents, 
a brief description of time-series and an overview of the similarity measures methods 
considered. 
Chapter 3 exposes the methodology employed on this study. The sequence of experiments 
and where and how data was gathered to compose the case-study cohorts is explained. 
The approach followed to establish the range of similarity values to be seek is also 
detailed. 
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On Chapter 4 the full description of each implemented experiment is given. Similarity 
measurements were exhaustively computed for different cohorts to enable a pattern 
identification of cardiac DM comorbidities. 
Chapter 5 concentrates the results obtained for the experiments listed in the previous 
chapter and the conclusions driven, and as well general conclusions and indicates future 
research guidelines. 
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2. REVIEWED CONCEPTS 
This chapter presents an explanation about some main concepts, which are fundamental 
for the understanding of the upcoming chapters. 
It will be described how to interpret a cardiac signal, the importance of an ECG and how 
it relates with HRV, a review of time-series and an explanation of similarity measures 
approaches. The main idea of this thesis is finding a specific pathology pattern with the 
DM patients’ using different similarity measures. 
2.1. CARDIAC SIGNALS 
The human heart’s electrical system controls all the events that occur when the heart 
pumps blood. This electrical system is also called cardiac conduction system. We can see 
a graphical picture of the heart’s electrical activity in an ECG. [5, 6] 
2.1.1. ELECTROCARDIOGRAM 
As it was mentioned, the ECG is the electrical manifestation of the contractile activity of 
heart, and can be recorded easily with surface electrodes on the limbs and chest. The ECG 
is one of the most commonly known and used biomedical signal. [6] 
Many researches developed methods of ECG analysis over the centuries, which improved 
significantly our understanding of ECG as a clinical tool [7]. Nowadays, the ECG is an 
essential part of the initial evaluation of patients presenting cardiac complaints. [8] 
It is not hard to understand why this biomedical signal is so recognized and, most likely, 
the most used biomedical signal. The rhythm of the heart in terms of beats per minute 
(bpm) is easily estimated by counting the peaks of the signal. But more important is the 
fact that the ECG shape is altered by CVDs and abnormalities such as myocardial 
ischemia and infarction, ventricular hypertrophy, and conduction problems. [6] 
In Figure 2.1., we have a typical ECG signal of a healthy person. 
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Figure 2.1 A typical ECG signal (male subject of 24 years old) [6] 
In the Figure above we have represented an ECG signal, where its components are marked 
as P wave which records the electrical activity through the atria, as QRS complex which 
records the movements of electrical impulses through ventricles, as ST segment which 
shows when the ventricle is contracting but there is no electricity flowing thought it and 
finally as T wave which shows when the lower heart chambers are resetting electrically 
and preparing for their next muscle contraction [9]. 
2.1.1.1. ECG Data Acquisition 
2.1.1.1.1. Standard 12-Lead ECG 
Usually, in clinical practise, the standard 12-Lead ECG is obtained using four limbs leads 
and six chest leads in different positions. The right leg is used to place the reference 
electrode. The left, right arm and left leg are used to get leads I, II and III. A combined 
reference knows as Wilson’s central terminal is formed by combining the left arm, right 
arm and left keg leads, and is used as the reference for chest leads. The augmented limb 
leads known as aVR, aVL and aVF, where aV stands for the augmented lead, R for the 
righ arm, L for the left arm and F for the left foot. These leads are obtained by using the 
exploring electrode on the limb indicated by the lead name, with the reference being 
Wilson’s central terminal without the exploring limb lead [6], which can be seen in the 
Figure 2.2. 
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Figure 2.2 Einthoven’s triangle and the axes of the six ECG leads formed by using limb leads. [6] 
The six chest leads, which are V1-V6, are obtained from six standardized position on the 
chest with Wilson’s central terminal as reference [6]. Which is represented in the Figure 
2.3. 
 
Figure 2.3 Positions for placement of the chest leads V1-V6 for ECG, auscultation areas for heart sounds, and pulse 
transducer positions for the carotid and jugular pulse signals. [6] 
These 12-lead system serves as the basis of the standard clinical ECG, its interpretation 
in mainly empirical, based on experimental knowledge. In the Figure 2.4, we have an 
example of a standard 12-lead ECG representation [6]. 
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Figure 2.4 Standard 12-lead ECG signals of a healthy male adult. [10] 
2.1.1.1.2. Frank Lead system 
In 1956 Frank described the heart as a rotating dipole within space. In principle, a rotating 
dipole works like a battery with a positive and negative pole spinning in space. Frank 
asked himself how the rotating dipole could be effectively being measured and described. 
He placed the electrodes on the body so the measured leads X, Y and Z were placed in a 
row, thereby making a cartesian coordinate system represented in the Figure 2.5. [11]  
This system may not substitute but complement Standard 12-Lead ECG. [12]  
 
Figure 2.5 The vector ECG views the heart as a rotating dipole. Electrode Position/Vertical Axes. [11] 
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In the Figure 2.6 we have an example of Frank’s Lead ECG signal. 
 
Figure 2.6 Frank Lead ECG signal. [13] 
For further reading visit [14]. 
2.2. HEART RATE VARIABILITY 
The heart rate variability measures the specific changes in time between successive heart 
beats. The time between beats is measured in milliseconds (ms) and is called a “R-R 
interval”. And it is represented in the Figure 2.7 [15] 
 
Figure 2.7 Heart rate variability. [15] 
The HRV is a non-invasive and sensitive technique to evaluate cardiovascular autonomic 
control [16]. A low HRV is related with stress, negative psychosocial events and CVD’s. 
It is also associated with a 32-45% increased risk of a first cardiovascular event in 
populations without known CVD  [15, 17]. 
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2.3. TIME-SERIES 
A time-series represents a collection of values obtained from sequential measurements 
over time [18].  
Recently, the increasing usage of time-series, has encouraged multiple researches to 
develop related data mining techniques [19]. Time-series is an important class of temporal 
data objects, and it can be easily obtained from scientific and financial applications (e.g. 
ECG, daily temperature, weekly sales totals, and prices of mutual funds and stocks) [4]. 
In this context, time-series data mining fundamental problem is what method should be 
used to obtain data classification with precision and accuracy. 
To avoid inaccuracies, before any data mining task, pre-processing techniques like 
normalization and noise removal are required. 
Moreover, similarity measure between time-series and segmentation are two core tasks 
for various time-series mining processes. Based on the time-series representation, 
different mining tasks can be found in the literature and they can be roughly classified 
into four fields: pattern discovery and clustering, classification, rule discovery and 
summarization. Some of the researches concentrates on one of these fields, while the 
others may focus on more than one of the above processes [4, 20, 19].  
In this thesis, the process is to find a pattern in DM patients and consequently perform 
clustering.  
 One of the major reasons for time-series representation is to reduce the dimension (i.e. 
the number of data points) of the original data. The simplest method it might be sampling. 
In this method, a rate of m/n is used, where m is the length of a time series P and n is the 
dimensionality reduction. However, the sampling method has the disadvantage of 
distorting the shape of compressed time series (if the sampling rate is too low), which can 
be seen in [18]. 
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 Figure 2.8 Time series dimensionality reduction by sampling [18]. 
However, there are better option, for instance reducing the dimension by preserving 
salient points, these points are called as perceptually important points (PIP). We can see 
the improvement in Figure 2.9 [18]. 
 
Figure 2.9 Time series compression by data point importance [18]. 
However, we still have a loss of information, this is the reasoning we also consider 
frequency transform based methods to measure similarity among different time-series, in 
the upcoming section, since they can reduce its dimensionality without any significant 
losses. 
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2.4. SIMILARITY MEASURES 
A usual data mining task is the estimation of similarity among objects. Normally, 
similarity among series is represented as [0, 1], where “one” it’s the absolute maximum 
for similarity [20]. 
If we work with an efficient and effective method of measuring similarity, we can find a 
relation among the time-series. This will greatly increase our accuracy and prediction on 
our analysis [20].  
There are two main groups of similarity measures, which are time domain and 
transformed based methods, but before choosing one we need to know the characteristics 
of those methods [20, 21].  
2.4.1. TIME DOMAIN METHODS 
Usually approaches using time domain methods are the simplest, computationally 
speaking this doesn’t mean that time domain methods are always faster than the 
transformed based methods, it depends how long and complex the time series are.  
In this sub chapter, it is briefly explained methods like Minkowski distance, Euclidean 
distance (ED), Dynamic time warping (DTW), Mahalanobis distance and Correlation 
coefficient.  
As it was mentioned in 2, the similarity measures presented follow the reasoning 
presented in [20], since both researches are included in the same research project.  
2.4.1.1. Euclidean Distance 
If we consider two time-series 𝑇(𝑡) = {𝑡(1), 𝑡(2),… , 𝑡(𝑁)} and 𝑆(𝑡) =
{𝑠(1), 𝑠(2),… , 𝑠(𝑁)} we can estimate the similarity between those series by measuring 
the distance between each of their pair of points, the lesser the distance the greater the 
similarity and vice versa [20, 21].  
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So, the Euclidean distance is represented by: 
𝐷𝐸(𝑇(𝑡), 𝑆(𝑡)) = (∑|𝑇(𝑡) − 𝑆(𝑡)|
2
𝑁
𝑡=1
)
1
2
 (1) 
On the other hand, this method is hard to use in some applications due to its drawbacks. 
As examples, the distance in this method can only be measured in straight-line, so we can 
only compare time-series with the same length, it doesn’t handle noise and it is very 
sensitive to signal transformations (Shifting, uniform amplitude scaling, uniform time 
scaling, uniform bi-scaling, time warping and non-uniform amplitude scaling) [20, 21]. 
 
Figure 2.10 T and S are two time-series of a variable v, along the time axis t. The Euclidean 
distance results in the sum of the point-to-point distances, along all the time series [21]. 
To overcome these issues, changes have been made on the principle of DTW [20, 21]. 
2.4.1.2. Dynamic Time Warping 
Dynamic time warping gives more robustness of the similarity computation, although it 
is also computationally expensive. With this method, we can compare time-series with 
different lengths since one-to-one point comparison (which was used in Euclidean 
distance method) was replaced by a many-to-one (or vice-versa) approach. This 
improvement allows DTW to recognize shapes, even with signal transformations [21]. 
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Figure 2.11 Difference between DTW distance and Euclidean distance. The former allows many-to-one point 
comparisons, while Euclidean point-to-point distance (or one-to-one) [21]. 
 
Given two time-series 𝑇(𝑡) = {𝑡(1), 𝑡(2), … , 𝑡(𝑁)} and 𝑆(𝑡) = {𝑠(1), 𝑠(2), … , 𝑠(𝑀)} 
where N and M represent respectively the length of the series, DTW method exploits 
information contained in a 𝑁𝑥𝑀distance matrix, as it follows [20, 21] : 
𝑑𝑖𝑠𝑡𝑀𝑎𝑡𝑟𝑖𝑥 = (
𝑑(𝑇1,𝑆1)   𝑑(𝑇1,𝑆2) …  𝑑(𝑇1,𝑆𝑀)
𝑑(𝑇2,𝑆1)   𝑑(𝑇2,𝑆2)                          
   ⋮                             ⋱                
𝑑(𝑇𝑁,𝑆1)                        𝑑(𝑇𝑁,𝑆𝑀)
) (2) 
where distMatrix (i, j) corresponds to the distance of ith point of T and jth point of S. 
The DTW objective is to find the warping path W = {w1, w2, …, wk, ..., wK} of contiguous 
elements on distMatrix such that it minimizes the following function [21]: 
𝐷𝑇𝑊(𝑇(𝑡), 𝑆(𝑡)) = 𝑚𝑖𝑛
(
 √∑𝑤𝑘
𝐾
𝑘=1
)
  (3) 
The warping path can be efficiently computed using dynamic programming. Using this 
method, a cumulative distant matrix γ of the same dimension as the distMatrix, is created 
to store in the cell (i, j) the minimum distance among adjacent cells (optimal path) [20, 
21]. 
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Figure 2.12 Warping path computation using dynamic programming [21]. 
In many cases, this method can bring unexpected results. For example, when many points 
of a time-series T are mapped to a single point of another series S. A common way to fix 
these events is to restrict the warping path in such a way that it must follow a direction 
along diagonal [21].  
 
 
Figure 2.13 Different mappings obtained with the classic implementation of DTW (a), and with the restricted path version 
using a threshold δ = 10 (b). [21]. 
 
In Figure 2.13, we fixed our results by restricting the DTW method with the previous method 
[20, 21]. For further reading please visit [21].  
2.4.1.3. Minkowski Distance 
This method is one of the simplest time domain methods and can be considered as a 
generalization of the Euclidean distance [20, 21].  
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The Minkowski distance is represented as: 
𝐷𝑀𝑖𝑛𝑘𝑜𝑤𝑠𝑘𝑖(𝑇(𝑡), 𝑆(𝑡)) = (∑|𝑇(𝑡) − 𝑆(𝑡)|
λ
𝑁
𝑡=1
)
1
𝜆
 (4) 
Where λ ≥ 1. 
In the case of λ=1 we have the same concept of Manhattan distance method, when λ=2 
we have Euclidean distance method [20, 21]. 
2.4.1.4. Mahalanobis Distance 
The Mahalanobis distance is defined as a dissimilarity measure between time-series with 
the same statistical distribution and the covariance matrix C of the multivariate random 
variable. 
It is defined as: 
𝐷𝑀𝑎ℎ𝑎𝑙𝑎𝑛𝑜𝑏𝑖𝑠(𝑇(𝑡), 𝑆(𝑡)) = ((𝑇(𝑡) − 𝑆(𝑡))
𝑇
𝐶−1(𝑇(𝑡) − 𝑆(𝑡)))
1
2
 (5) 
The advantage of using this method is that is takes into consideration the correlations 
between the time-series stocked in matrix C. Because of this we can identify different 
patterns and analyse them based on a reference point [20, 21]. 
2.4.1.5. Pearson’s Correlation Coefficient 
Pearson’s method is a statistical measure which measures the strength of a linear 
relationship between paired data. 
 It is invariant to shifting and scaling, being expressed when applied to a sample as [20]: 
𝑟𝑃𝐶𝐶 =
∑ (𝑇𝑖 − ?̅?)(𝑆𝑖 − 𝑆̅)
𝑁
𝑖=1
√∑ (𝑇𝑖 − ?̅?)
𝑁
𝑖=1
2√∑ (𝑆𝑖 − 𝑆̅)
𝑁
𝑖=1
2
 
(6) 
Where N is the number of samples, 𝑇𝑖 and 𝑆𝑖 are single samples indexed with i. Lastly 
but not least, ?̅? and 𝑆̅ are the sample mean, represented as: 
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?̅? =
1
𝑁
∑𝑇𝑖
𝑁
𝑖=1
 𝑎𝑛𝑑 𝑆̅ =
1
𝑁
∑𝑆𝑖
𝑁
𝑖=1
 (7) 
These samples are constrained by default between -1 and 1. The closer the value is to 1 
or -1, the stronger the linear correction is. Positive values denote positive linear 
correlation, negative values denote negative linear correlation and zero value means that 
there is no correlation [20, 22]. 
This method presents the advantage of being unaffected by dispersion differences across 
linear transformations. [20] 
2.4.2. TRANSFORMED BASED METHODS 
It was already stated that one of the goals while mining time-series data, is to work with 
a representation with fewer data points than the raw data, this can be achieved by reducing 
its dimensionality, while maintaining its main properties [21]. 
According to the results of previous researches [23, 20] the Transform based methods 
used in this work were Discrete Cosine Transform (DCT) and Discrete Wavelet 
Transform (DWT), and they will be briefly explained. 
2.4.2.1. Discrete Fourier Transform 
The Discrete Fourier Transform (DFT) is a typical data reduction technique which was 
used to map time-series data from the time domain to the frequency domain [20, 19, 23]. 
The basic idea of Fourier Transform is to decompose a signal, where any signal can be 
represented as a sine and cosine basis function, each function being known as a Fourier 
coefficient. The most important feature of this method is data compression, which allows 
us to reconstruct the original signal by the corresponding waves with higher Fourier 
coefficients. By taking into consideration only the first Fourier coefficients for indexing 
they effectively reduce the search space and speed-up the similarity query [20, 19]. 
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The exponential representation of DFT in frequency domain could be defined as: 
𝑇(𝐹) = 𝐷𝐹𝑇(𝑇(𝑡)) =
1
√𝑁
∑ 𝑇(𝑖)𝑒−
𝑗2𝜋𝐹𝑖
𝑁
𝑁−1
𝑖=0
 (8) 
Where F=0, …, N-1, 
𝑒−
𝑗2𝜋Fi
𝑁 = 𝑐𝑜𝑠 (
2𝜋Fi
𝑁
) + 𝑗𝑠𝑖𝑛 (
2𝜋Fi
𝑁
) (9) 
From Euler’s equation, we can conclude that the Fourier Transform (FT) decompose 
time-series into periodic signals in the frequency domain, where cosine functions 
represent the real part of the spectrum and the sine functions the imaginary part of the 
spectrum [20, 23, 19].  
Similarly, to [20], it was used Discrete Cosine Transform (DCT) as a similarity method, 
where it only uses the real part of the spectrum, which will be briefly explained in the 
next sub-chapter. 
A fundamental property of DFT is guaranteed by Parseval’s Theorem, which asserts that 
the energy calculated on the time-series domain for signal f is preserved on the frequency 
domain. [20, 23, 19] 
The energy E(f) of a signal f is given by: 
𝐸(𝑓) = ∑|𝐹(𝑘)|2 = 𝐸(𝐹)
𝑁−1
𝑘=0
 (10) 
If we use the Euclidean distance method, by this property, the distance calculated between 
two signals in time domain will be the same as in the frequency domain. The reduced 
representation is built by only keeping the first k coefficients.  
The main drawback of DFT is the choice of the best number of coefficients to keep for a 
good reconstruction of the original signal [20, 19, 24, 21]. 
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2.4.2.1.1. Discrete Cosine Transform 
As mentioned in 2.4.2.1. DCT is the real part of the FT and for a time-series with length 
of N, 𝑇(𝑡) = {𝑡(1), 𝑡(2), … , 𝑡(𝑁)} is derived from a simplified form of equation (8) that 
is shown below: 
𝑇′(𝑡) =  𝑝(𝑡)∑𝐶𝑘 𝑐𝑜𝑠 〈
𝜋(2𝑘 − 1)(𝑡 − 1)
2𝑁
〉
𝑁
𝑘=1
 (11) 
In equation (11), t=, …, N, the parameters 𝐶𝑘 are scale factors of the cosine wave and 
𝑝(𝑡) represents a normalization coefficient that could be defined as equation (12): 
𝑝(𝑡) =
{
 
 
 
 
1
√𝑁
    , 𝑡 = 1
√
2
𝑁
     , 2 ≤ 𝑡 ≤ 𝑁
                                                 (12) 
For measuring the similarity between two time-series T(t) and S(t) based on DCT 
coefficients, the first m coefficients could represent a good approximation of time-series 
so this distance could be a good measure of similarity. The template signal, T(t), and the 
added variation signal, S(t), are decomposed into DCT coefficients and the similarity is 
measured according equation (13): 
𝐷𝐷𝐶𝑇(𝑇 
 (𝑡), 𝑆(𝑡)) = √∑(𝐶𝑘 𝑇 − 𝐶𝑘𝑆)
2
𝑚
𝑘=1
    (13) 
This distance could be the same as the Euclidean distance if we consider all coefficients 
m=N [20, 23].  
Similarly to [20], in this work was considered the first m=4 coefficients to achieve 90 
percent of accuracy on the approximation. 
2.4.2.2. Discrete Wavelet Transform 
Discrete Wavelet Transform (DWT) was proposed to replace DFT. This new technique 
has several pros over the DFT.  
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It provides time and frequency information simultaneously, it is more flexible (a wide 
range of different DWT bases exist, whereas the DFT is just based on cos and sin with 
different frequencies) and it has more discrimination power than DFT. The cost of these 
advantages is greater computational complexity, the flexibility which was an advantage 
can also be considered as a disadvantage once it can be hard to choose which basis to use. 
Also, the results are harder to interpret (less intuitive) [20, 19]. 
The basic idea of Wavelet Transform is data representation in terms of sum and difference 
of prototype functions, known as wavelets. Similarly, to DFT, wavelet coefficients give 
local contributions to the reconstruction of the signal, while Fourier coefficients always 
represent global contributions to the signal over time [20, 19, 24, 21]. 
There are plenty of wavelet’s families, although in this work, similarly to [20], we will 
be using Haar which is the simplest possible wavelet. An example of DWT based on Haar 
is shown in the 
Table 2-1. 
The general Haar transform 𝐻𝐿(𝑇) of a time-series T of length n can be formalized as in 
equation (14): 
𝐴𝐿′+1(𝑖) =
𝐴𝐿′(2𝑖) + 𝐴𝐿′(2𝑖 + 1)
2
 
𝐷𝐿′+1(𝑖) =
𝐷𝐿′(2𝑖) − 𝐷𝐿′(2𝑖 + 1)
2
 
𝐻𝐿(𝑇) = (𝐴𝐿 , 𝐷𝐿 , 𝐷𝐿−1, … , 𝐷0)  
(14) 
Where 0 < 𝐿´ ≤ 𝐿, and 1 ≤ 𝑖 ≤ 𝑛. 
Level (L) Averages coefficients (A) Wavelet Coefficients (D) 
1 10,4,6,6  
2 8,6 3,0 
3 7 1 
 
Table 2-1 The Haar Transform. [21] 
 
In the Table 2-1, we have the Haar transform.of T = {10, 4, 8, 6} depends on the chosen 
level, and corresponds to merging Averages coefficients (column 2) at the chosen level 
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and all Wavelet coefficients (column 3) in decreasing order among the chosen level. At 
level 1 the representation is the same as time series. H1(T) = {10, 4, 6, 6} + {} = {10, 4, 
6, 6} = T. At level 2, H2(T)= {8, 6} + {3, 0} + {} = {8, 6, 3, 0}. At level 3 is H3(T) = 
{7} + {1} + {3, 0} = {7, 1, 3 0}. [21] 
Decomposing a signal with wavelets, it should be mentioned that two types of filter are 
used. A high-pass filter (HPF) and a low-pass filter (LPF), as it is represented in the figure 
below: 
 
Figure 2.14  Splitting the signal spectrum with an iterated filter bank [25]. 
If we regard the wavelet transform as a filter bank, we can consider the wavelet 
decomposing a signal as passing through this filter bank. We split the signal spectrum in 
two equal parts, a LPF and a HPF part, where the LPF applies a scaling function while 
the HPF applies the wavelet function. Once the functions were applied what will remain 
in the LFP part would be an approximation of the signal and in the HPL part would be 
the details of the signal. We can keep splitting the spectrum until we are satisfied with the 
detail and scale of the lighter version of the signal, which can be limited by the amount 
of resources or the computational power available. We can see in the figure below the 
decomposition tree, where its resolution depends on the different scale and detail (levels) 
[20, 21, 25]. 
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Figure 2.15 Decomposing tree and its respective level of decomposition [26] 
Time-series can be decomposed into linear combinations of the basis-functions. So, the 
signal could be approximated by different resolutions through the following equation: 
𝑇′(𝑡) =  ∑𝜑𝑗(𝑡)
𝐽
𝑗=1
 (15) 
J represents the level of decomposition and 𝑇′(𝑡) is an approximation of the time-series 
and its accuracy is dependent on the level of the basic functions 𝜑𝑗(𝑡) that are used to 
reconstruct the signal. These functions are orthogonal and generated by multiplication of 
the coefficients 𝑑𝑗 ∈ ℝ, which are scalers, with different orthogonal wavelet basis   𝜓𝑗(𝑡), 
so: 
𝜑𝑗(𝑡) = 𝑑𝑗  𝜓𝑗(𝑡) (16) 
The trend of the input function is captured in approximation to the original function ϕ(t), 
while localized changes are kept as sets of detailed functions, ranging from coarse to fine 
ψ(t). If we consider, 𝜑1(𝑡) =  𝐶0,0𝜙0,0(𝑡) and J as level of decomposition and  𝑗 =
log2𝑁, then DWT is computed as it shows: 
?̃?𝑗(𝑡) = 𝐶0,0𝜙0,0(𝑡) + ∑ ∑ 𝑑𝑗,𝑘𝜓𝑗,𝑗(𝑡)
2𝑗−1
𝑘=0
𝑗−1
𝑗=0
 (17) 
Exploring the data reduction ability of DWT for measuring the similarity between time-
series, in this work we followed this methodology by combining the Haar wavelet 
decomposition with the Karhunen-Loève transforms (KLT) to optimally reduce the 
number of wavelet basis [20, 25]. 
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2.4.2.3. Karhunen-Loève Transform 
When we measure the similarity with DWT combined with KLT, the distance between 
time-series is measured but the reduced number of coefficients are considered according 
Karhunen-Loève theorem. This method decomposes the time-series into the basic 
functions which are orthogonal to each other. 
Those are obtained as eigenvectors of the covariance matrix composed of the wavelet 
basis [23]. The approximation of the signal is acquired by reducing the number of basis 
that have been employed in the similarity measuring instead of reducing the signal. This 
reduction is obtained from the first highest J eigenvalues of the correspondent covariance 
matrix [23]. 
The first step is to decompose the template time-series 𝑇(𝑡), with length N, into a linear 
combination of N wavelet basis 𝜑𝑗(𝑡), equation (18) [23]. 
𝑇 
 (𝑡) =  ∑𝜑𝑗(𝑡)           
𝐽
𝑗=1
 (18) 
The next step is to decompose the second time-series 𝑆(𝑡), with the same length of N, 
into the same wavelet basis 𝜑𝑗(𝑡), equation (19) [23]. 
𝑆(𝑡) =  ∑  𝛼𝑗  𝜑𝑗(𝑡)           
𝐽
𝑗=1
 (19) 
Where the coefficients  𝛼𝑗 could be derived into equation (20) [23]. 
 𝛼𝑗 =
〈𝑆(𝑡), 𝜑𝑗(𝑡)〉
〈𝜑𝑗(𝑡), 𝜑𝑗(𝑡)〉
 (20) 
Where < > stands for inner product. 
 As in FT, the distance of these coefficients could show similarity between two time-
series, as it is represented in equation (21) [23]. 
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𝐷𝐷𝑊𝑇(𝑇(𝑡), 𝑆(𝑡)) = √∑(1 −  𝛼𝑗)
2
𝐽
𝑗=1
 (21) 
If we consider all set of basis J=N, the result would be the same as the Euclidean distance. 
The most important feature of this method is to reduce noised data and to reduce 
unnecessary parts of the signal [23]. 
Similarly to [20], this thesis set all signals’ length to N=1024 and J=4 to achieve 92% 
accuracy in the approximation. 
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3. METHODS AND EXPERIMENTS 
As mentioned before, measuring similarity within time-series plays an important role in 
finding a pattern, enabling prediction and knowledge discovery.  
Since clinical signals are random processes with non-stationary characteristics and each 
individual has its own, we can consider electrocardiograms like fingerprints where it is 
literally impossible to achieve similarity of 1, this is 100%. So, in this thesis, we are 
interested in observing how different similarity measurements methods performs between 
two time-series varies. With this we can make a statistical study in order to know which 
methods and ECG leads (below synthetically said leads) have the best performance when 
it comes to measuring similarity. 
A primary experiment was made to know which are the best leads and similarity measures 
when we are measuring similarity between two time-series. On this experiment, we only 
took in consideration a cohort with patients with the same diagnosis, gender and age 
range. 
After knowing that, we took a second experiment to find a pattern for a specific cardiac 
pathology. On this experiment, we have used a cohort where patients have different 
diagnosis with DM as reference. 
In both experiments we are not measuring similarity between whole time-series, but with 
specific cardiac cycles of both series. Comparing whole ECG signals would result in 
erroneous results, since in thirty seconds of the time-series the number of cardiac cycles 
of each patient is variable. 
3.1. IMPLEMETATION OF SIMILARITY MEASURING METHODS 
To apply similarity measuring methods we need pairs of time-series, where one is the 
template and the other one is the one we want to measure the similarity with.  
The time-series data were collected from the public data base PhysioNet [13]. The 
similarity measuring methods considered were the ones described in section 2.4. 
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3.2. DATA ACQUISITION 
All data used in this thesis were collected from PhysioNet database [13]. This platform 
offers free web access to a large amount of biomedical data, many of them including 
clinical annotations.  
In both experiments described in the next sections, the biomedical signals selected were 
ECGs collected from The PTB Diagnostic data base and only thirty seconds of that data 
was considered, which contains 549 records from 290 subjects (aged 17 to 87, mean 57.2; 
209 men, mean age 55.5, and 81 women, mean age 61.6 with different heart diseases. 
PTB is an abbreviation for Physikalisch-Technische Bundesanstalt, the National 
Metrology Institute of Germany, which has provided this digitized ECGs for research. 
The sampling frequency in this database is 1000 Hz [13]. 
Both experiments required specifically developed software programs, which were 
implemented using Matlab software [27]. 
3.3. PRE-PROCESSING 
In the real life, all the data collected from devices and sensors are subject to different 
kinds of noise and artefacts. The first and the most important step is to overcome this 
issue by performing some pre-processing, which includes noise filtering, normalization, 
transformations, feature extraction and data selection. Increasing the quality of the data 
will greatly reduce the probability of misleading results. The noise filtering can be 
handled by using digital filters or wavelet thresholding. By performing a normalization 
of the data, all values are adjusted in a common scale into the range [0, 1], this process is 
also called unity-based normalization which is presented in equation (22). 
𝑋′  =
𝑋 −  𝑋𝑚𝑖𝑛
𝑋𝑚𝑎𝑥 − 𝑋𝑚𝑖𝑛 
 (22) 
Another pre-processing method is the removal of vertical offsets, which is described in 
equation (23). 
𝑋′ = 𝑋 − ?̅? (23) 
Where ?̅? is the mean value of the signal. 
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Another issue to take into consideration is the scaling difference between time-series. In 
this thesis, we are measuring similarity between ECG’s signals whose range of amplitude 
values varies widely. Since the similarity measuring methods are based on computing the 
point to point distance between both time-series these variations will produce misleading 
results. This problem can be fixed using linear transformation on the amplitudes. 
Another important issue to consider is that, we must have time-series with the same 
duration to enable computation of their similarity. So, we must take into consideration 
the fact that each patient has different cardiac cycles duration. In this thesis, to overcome 
this problem the ECG’s cardiac cycles were centred by QRS complex and the minimum 
common number of points was considered which means a loss of information.  
3.4. EXPERIMENTS 
3.4.1. EXPERIMENTS FOR FINDING THE MOST REPRESENTATIVE 
LEADS IN TERMS OF SIMILARITY VALUES WITHIN COHORTS  
As it was mentioned previously on section 2.4, a similarity measuring method should be 
able to identify similarity between time-series despite the small variations that occur cycle 
to cycle.  
The main goal of this experiment is to measure similarity between time-series from 
patients with same diagnosis, with this we will able to find which similarity measuring 
methods and leads are the most effective in identifying similarity among series with a 
certain pathology in common. 
In order to increase the reliability of these experiments, the measurements between time-
series were calculated for three different cardiac cycles. The cardiac cycles selected were 
the maximum and the minimum in terms of duration, plus the cardiac cycle between time-
series that would result in less loss of information (closer to each other in terms of 
duration). 
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3.4.2. EXPERIMENT FOR FINDING A PATTERN ON DM PATIENTS 
After identifying the best leads and similarity measuring methods our goal is to find a 
pattern of a cardiac disease in DM patients, to do so, several comparisons were made. 
 Firstly, a performance reference was needed. It is known that each cardiac cycle for a 
specific patient may vary in form and length, so it was required to know what value of 
performance (in this case, similarity) would represent the best similarity. 
So, we started by computing the similarity between two ECG signals collected from the 
same patient (this patient has Myocardial infarction and diabetes mellitus). By 
considering measuring similarity between cardiac cycles of the same ECG record of a 
patient we were aiming to achieve a similarity value close to 1.  
The first step was to measure the similarity between two ECG cardiac signals from the 
same individual collected with two weeks of difference (this patient presented myocardial 
infarction and diabetes mellitus), to find our upper bound. 
The second step was to measure the similarity between two ECG signals from different 
patients but with the same diagnosis (these patients have Myocardial infarction and 
diabetes mellitus). 
The third step was to measure the similarity between two ECG cardiac signals from 
different patients and different diagnosis (this cohort included patients with Myocardial 
infarction and diabetes mellitus in common but with additional different pathologies). 
Lastly, the similarity between two ECG cardiac signals was computed between a healthy 
individual and a patient (this patient has Myocardial infarction and diabetes mellitus), and 
we hypothesised that this would determine the lower bound of the similarity performance 
range. 
In order to increase the reliability of these experiments, the measurements between time-
series were calculated with three different types of cardiac cycles’ lengths. The cardiac 
cycles selected were the ones presenting the maximum and the minimum in terms of 
duration, plus the cardiac cycle length which would result in less loss of information 
(closer to each other in terms of duration). To be noticed that his procedure was not 
applied to the above mentioned first experiment. 
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4. RESULTS AND ANALYSIS 
4.1. CASE-STUDIES 
The Physionet [13] data considered in this study is listed in Table 4-1 where the name of 
the database record is specified as well as the characterization of the patients’ information. 
Number Gender Age ECG date Diagnosis Smoker 
Blood 
pressure 
S0004 Female 79 14/08/1990 myocardial infarction  
diabetes mellitus 
NO ND 
S00101 Female 81 01/10/1990 myocardial infarction  
diabetes mellitus 
NO 140/80 
mmHg 
S00142 Female 81 17/10/1990 myocardial infarction  
diabetes mellitus 
NO 140/80 
mmHg 
S0045 Female 71 14/11/1990 myocardial infarction  
diabetes mellitus 
renal insufficiency 
YES 130/80 
mmHg 
S0052 Male 63 17/11/1990 myocardial infarction 
diabetes mellitus  
hyperuricemia 
NO 120/70 
mmHg 
S0088 Female 74 03/01/1991 myocardial infarction  
diabetes mellitus 
NO 160/90 
mmHg 
S0227 Male 59 18/09/1991 myocardial infarction,  
diabetes mellitus 
arterial hypertension 
YES 120/60 
mmHg 
S0303 Female 32 24/06/1992 Healthy Control ND ND 
S0311 Female 69 21/07/1992 Healthy Control ND ND 
S04623 Female 25 17/10/1996 Healthy Control ND ND 
Table 4-1 Patients’ information (ND – no information available). 
The records employed were gathered into different cohorts, as described in Table 4.2. 
  
                                                 
1 - This is our template signal for DM patients. 
2 - S0010 and S0014 are the same individual 
3 - This is our template signal for Healthy Controls. 
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Cohort Characteristics Sub-division of Cohorts Patients 
1 Same Patient 
1.1 S0010 
1.2 S0014 
2 
Different Patients 
with the same diagnosis 
2.1 S0088 
2.2 S0004 
3 
Different Patients 
with different diagnosis 
3.1 S0052 
3.2 S0045 
3.3 S0227 
4 Healthy controls 
4.1 S0462 
4.2 S0303 
4.3 S0311 
Table 4-2 Cohorts’ information. 
4.2. EXPERIMENTS FOR FINDING THE MOST REPRESENTATIVE 
LEADS IN TERMS OF SIMILARITY VALUES WITHIN COHORTS  
As mentioned in section 3.4.1, similarity measurements of ECG cardiac cycles of patients 
with the same diagnosis were tested, this is, an evaluation of the most adequate range of 
similarity performance to be considered in each experiment and the evaluation of 
similarity measurements between time-series of cardiac cycles of patients with the same 
diagnosis was performed for each ECG lead. The through description of the experiments 
is below presented, being graphically exemplified only for some cases, due to the large 
amount of information available. The table with similarity measurements results may be 
found in Appendix.   
4.2.1. SIMILARITY MEASUREMENTS BETWEEN THE SAME 
PATIENT 
In this experiment signals s0010 and s0014 were collected from the same individual but 
the ECG signal from s0014 was collected two weeks after s0010. The first step is to 
identify the cardiac cycles of both ECG signals. In the Figure 4.1, it is represented the 
cardiac cycles of patient s0010 (a) and patient s0014 (b). 
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(a) 
 
(b) 
Figure 4.1  The cardiac cycles of (a) s0010 patient (b) s0014 patient, where the x-axis represents the number of 
cardiac cycles and the y-axis the duration of those cycles.  
It was observed that for patient s0010 the 13th cardiac cycle was the minimum cardiac 
cycle while the maximum one was the 40th cardiac cycle, so the HRV is 22ms. For patient 
s0014 the minimum was found for the 24th cardiac cycle and the maximum for the 8th, 
thus the HRV is 13ms. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 8th cardiac cycle of the patient s0014. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 24th cardiac cycle of the patient s0014. 
The last comparison will be between the 13th cardiac cycle of the patient s0010 and the 
8th cardiac cycle of the patient s0014, this will result in losing only one data point of 
information. 
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4.2.1.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with longer data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. So, the following graphs (Table 4.2) show the comparison between the 40th 
cardiac cycle of the s0010 patient with the 8th cardiac cycle of the patient s0014. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 30 94 4.2 
L2 𝑆𝐶𝐶 38 86 4.3 
L3 𝑆𝐶𝐶 16 94 4.4 
V1 𝑆𝐶𝐶 24 86 4.5 
V2 𝑆𝐶𝐶 23 88. 4.6 
V3 𝑆𝐶𝐶 10 93 4.7 
V4 𝑆𝐶𝐶 7 92 4.8 
V5 𝑆𝐶𝐶 34 90 4.9 
V6 𝑆𝐶𝐶 30 81 4.10 
Vx 𝑆𝐶𝐶 14 89 4.11 
Vy 𝑆𝐶𝐶 51 74 4.12 
Vz 𝑆𝐶𝐶 44 86 4.13 
aVF 𝑆𝐶𝐶 4 90 4.14 
aVL 𝑆𝐶𝐶 12 96 4.15 
aVR 𝑆𝐶𝐶 23 80 4.16 
Table 4-3 Similarity between the 40th cardiac cycle of the s0010 patient with the 8th 
cardiac cycle of the patient s0014. 
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Figure 4.2 L1 lead. 
 
Figure 4.3  L2 lead. 
 
Figure 4.4 - L3 lead.  
 
Figure 4.5 - V1 lead.  
 
Figure 4.6 V2 lead.  
 
Figure 4.7 - V3 lead.  
0 100 200 300 400 500 600 700 800
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
L1
 
 
s0010
s0014
0 100 200 300 400 500 600 700 800
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
L2
 
 
s0010
s0014
0 100 200 300 400 500 600 700 800
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
L3
 
 
s0010
s0014
0 100 200 300 400 500 600 700 800
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
V1
 
 
s0010
s0014
0 100 200 300 400 500 600 700 800
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
V2
 
 
s0010
s0014
0 100 200 300 400 500 600 700 800
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
V3
 
 
s0010
s0014
33 
 
 
Figure 4.8 V4 lead.  
 
Figure 4.9 V5 lead.  
 
Figure 4.10 V6 lead.  
 
Figure 4.11  VX lead.  
 
Figure 4.12 VY lead.  
 
Figure 4.13 VZ lead.  
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Figure 4.14 aVF lead.  
 
Figure 4.15 aVL lead.  
 
Figure 4.16 aVR lead.  
4.2.1.2. Analysis 
In this experiment, it was concluded that Pearson’s correlation coefficient outperformed 
other similarity measurement methods for all leads. 
It was verified that the highest similarity among time-series was obtained progressively 
decreasing in the following leads: L1, L3, aVL, V3 and V4. 
 Since the Wavelet Transform KLT based method has been appointed in previous 
researches as being an accurate similarity method, we identified that the sequence of the 
best performed leads, from highest to lower was: VX, aVF, V4, V3, L1 and aVL. The 
performance of this method was good enough to be taken into consideration.  
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4.2.2. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
PATIENTS WITH THE SAME DIAGNOSIS - I 
In this experiment, signals s0010 and s0088 were collected from different individuals 
with the same diagnosis, this is, besides having diabetes mellitus they were diagnosed 
with myocardial infarction. In Figure 4.17 is represented the cardiac cycles of patient 
s0088. 
 
Figure 4.17 The cardiac cycles of s0088 patient, where the x-axis represents the number of cardiac cycles and the y-
axis the duration of those cycles.  
It was observed that for patient s0088 the 10th cardiac cycle was the minimum cardiac 
cycle while the maximum one was the 9th cardiac cycle, which represents a HRV of 32ms. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 9th cardiac cycle of patient s0088. It will be also compared the 
13th cardiac cycle of the patient s0010 with the 10th cardiac cycle of the patient s0088. 
The last comparison will be between the 40th cardiac cycle of the patient s0010 and the 
10th cardiac cycle of the patient s0088, this will result in losing thirty data points of 
information. 
4.2.2.1. Results 
Among these three comparisons it was observed that whenever longer data lengths were 
used for comparing the time-series the better the results were attained, independently of 
the ECG lead under study. So, only the best results will be presented below for the sake 
of thesis’ simplicity. 
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Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝑊𝑇 6 78 4.18 
L2 𝑆𝑊𝑇 24 47 4.19 
L3 𝑆𝐶𝐶 14 84 4.20 
V1 𝑆𝑊𝑇 31 41 4.21 
V2 𝑆𝐶𝐶 2 28 4.22 
V3 𝑆𝐶𝐶 14 51 4.23 
V4 𝑆𝐶𝐶 13 58 4.24 
V5 𝑆𝐶𝐶 12 55 4.25 
V6 𝑆𝑊𝑇 16 43 4.26 
Vx 𝑆𝑊𝑇 13 59 4.27 
Vy 𝑆𝐶𝐶 6 45 4.28 
Vz 𝑆𝐶𝐶 23 65 4.29 
aVF 𝑆𝐶𝐶 16 74 4.30 
aVL 𝑆𝐶𝐶 19 84 4.31 
aVR 𝑆𝑊𝑇 52 79 4.32 
Table 4-4 Similarity between the 40th cardiac cycle of the s0010 patient with the 9th 
cardiac cycle of the patient s0088. 
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Figure 4.18 L1 lead.  
 
Figure 4.19 L2 lead.  
 
Figure 4.20 L3 lead.  
 
Figure 4.21 V1 lead.  
 
Figure 4.22 V2 lead.  
 
Figure 4.23 V3 lead.  
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Figure 4.24 V4 lead.  
 
Figure 4.25 V5 lead.  
 
Figure 4.26 V6 lead.  
 
Figure 4.27 VX lead.  
 
Figure 4.28 VY lead.  
 
Figure 4.29 VZ lead.  
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Figure 4.30 aVF lead.  
 
Figure 4.31 aVL lead.  
 
Figure 4.32 aVR lead.  
4.2.2.2. Analysis 
In this experiment, we can conclude that Pearson’s correlation coefficient outperformed 
other similarities measurement methods in nine out of fifteen leads. However, unlikely 
the previous experiment, the Wavelet Transform KLT based method’s performances was 
not so far behind the Pearson’s correlation coefficient method. 
We verified that we have obtained the highest similarity among time-series in the 
following leads (from highest performance to lower): L3, aVL, aVF, L1, VZ and V4, 
these were the leads where Pearson’s correlation coefficient performed the best. 
 To be mentioned that the leads where Wavelet Transform KLT based method performed 
the best, were the following: aVR, L1, aVL, VX, L3 and aVF.   
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4.2.3. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
PATIENTS WITH THE SAME DIAGNOSIS - II 
In these experiments, the tested signals were collected from different patients with the 
same diagnosis as reported in last section, this is, myocardial infarction besides diabetes 
mellitus, but now comparison was performed between patient’s time-series s0010 with 
s0004. In Figure 4.33, it is represented the cardiac cycles of patient s0004. 
 
Figure 4.33 The cardiac cycles of s0004 patient, where the x-axis represents the number of cardiac cycles and the y-
axis the duration of those cycles.  
It was observed that for patient s0004 the 26th cardiac cycle was the minimum cardiac 
cycle while the maximum one was the 34th cardiac cycle, presenting a 19ms of HRV.     
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 34th cardiac cycle of the patient s0004. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 26th cardiac cycle of the patient s0004. 
The last comparison it will be between the 40th cardiac cycle of the patient s0010 and the 
26th cardiac cycle of the patient s0004, this will result in losing seventy-eight data points 
of information. 
4.2.3.1. Results 
Following the same methodology as previously, only the best performed results will be 
show, in this case, only the comparison between the 40th cardiac cycle of the patient s0010 
and the 26th cardiac cycle of the patient s0004 will be presented. 
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Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 28 59 4.34 
L2 𝑆𝑊𝑇 45 78 4.35 
L3 𝑆𝑀𝐴𝐻 9 38 4.36 
V1 𝑆𝑊𝑇 1 35 4.37 
V2 𝑆𝐶𝐶 10 88 4.38 
V3 𝑆𝐶𝐶 18 91 4.39 
V4 𝑆𝑊𝑇 9 87 4.40 
V5 𝑆𝑊𝑇 17 54 4.41 
V6 𝑆𝑊𝑇 32 61 4.42 
Vx 𝑆𝑊𝑇 10 64 4.43 
Vy 𝑆𝑀𝐴𝐻 2 35 4.44 
Vz 𝑆𝑊𝑇 12 80 4.45 
aVF 𝑆𝑀𝐴𝐻 11 30 4.46 
aVL 𝑆𝐶𝐶 9 63 4.47 
aVR 𝑆𝑊𝑇 6 58 4.48 
Table 4-5 Similarity between the 40th cardiac cycle of the s0010 patient with the 26th cardiac cycle of the patient 
s0004. 
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Figure 4.34 L1 lead. 
 
Figure 4.35 L2 lead. 
 
Figure 4.36 L3 lead. 
 
Figure 4.37 V1 lead. 
 
Figure 4.38 V2 lead. 
 
Figure 4.39 V3 lead. 
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Figure 4.40 V4 lead. 
 
Figure 4.41 V5 lead. 
 
Figure 4.42 V6 lead. 
 
Figure 4.43 VX lead. 
 
Figure 4.44 VY lead. 
 
Figure 4.45 VZ lead. 
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Figure 4.46 aVF lead.  
 
Figure 4.47 aVL lead.  
 
Figure 4.48  aVR lead.  
4.2.3.2. Analysis 
In this experiment, we can conclude that Pearson’s correlation coefficient was slightly 
outperformed by Wavelet Transform KLT based method. It will be once again considered 
the leads where these two methods performed the best. 
We verified that we have obtained the highest similarity among time-series in the 
following leads: V3, V2, V4, aVL, L1 and VZ, these were the leads where Pearson’s 
correlation coefficient performed the best. 
 Lastly, the leads where Wavelet Transform KLT based method performed the best, were 
the following: V4, VZ, V2, L2, V3 and VX.   
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4.2.4. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
HEALTHY CONTROLS - I 
In this experiment signals s0462 and s0303 were collected from distinct healthy 
individuals. In the Figure 4.49, it is represented the cardiac cycles of individual s0462 (a) 
and individual s0303 (b). 
  
(a) 
 
(b) 
Figure 4.49  The cardiac cycles of (a) s0462 healthy control (b) s0303 healthy control, where the x-axis represents the 
number of cardiac cycles and the y-axis the duration of those cycles. 
It was observed that for healthy control s0462 the 14th cardiac cycle was the minimum 
while the maximum was the 17th cardiac cycle, so the HRV of 157ms. For healthy control 
s0303 the minimum was found for the 12th cardiac cycle and the maximum for the 6th, 
thus the HRV is 65ms. 
So, to measure similarity in these patients it will be compared the 17th cardiac cycle of 
the s0462 patient with the 6th cardiac cycle of the patient s0303. It will be also compared 
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the 14th cardiac cycle of the patient s0462 with the 12th cardiac cycle of the patient s0303. 
The last comparison it will be between the 13th cardiac cycle of the patient s0462 and the 
37th cardiac cycle of the patient s0303, this will result in losing only two data points of 
information. 
4.2.4.1. Results 
The best performed results obtained for the time-series related to the cardiac cycles with 
closer data lengths are expressed in Table 4-6 and figures 4-50 to 4-64.. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 45 77 4.50 
L2 𝑆𝐶𝐶 36 81 4.51 
L3 𝑆𝐶𝐶 18 62 4.52 
V1 𝑆𝐶𝐶 15 82 4.53 
V2 𝑆𝐶𝐶 18 72 4.54 
V3 𝑆𝐶𝐶 3 60 4.55 
V4 𝑆𝐶𝐶 26 76 4.56 
V5 𝑆𝐶𝐶 20 86 4.57 
V6 𝑆𝐶𝐶 23 87 4.58 
Vx 𝑆𝐶𝐶 23 84 4.59 
Vy 𝑆𝐶𝐶 33 76 4.60 
Vz 𝑆𝐶𝐶 21 94 4.61 
aVF 𝑆𝑊𝑇 3 80 4.62 
aVL 𝑆𝑊𝑇 15 39 4.63 
aVR 𝑆𝐶𝐶 39 82 4.64 
Table 4-6 Similarity between the 13th cardiac cycle of the s0462 patient with the 37th cardiac cycle of the patient 
s0303. 
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Figure 4.50  L1 lead.  
 
Figure 4.51 L2 lead.  
 
Figure 4.52 L3 lead.  
 
Figure 4.53 V1 lead.  
 
Figure 4.54 V2 lead.  
 
Figure 4.55 V3 lead.  
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Figure 4.56 V4 lead.  
 
Figure 4.57 V5 lead.  
 
Figure 4.58 V6 lead. 
 
Figure 4.59 VX lead.  
 
Figure 4.60 VY lead.  
 
Figure 4.61 VZ lead.  
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Figure 4.62 aVF lead.   
 
Figure 4.63 aVL lead. 
 
Figure 4.64 aVR lead.  
4.2.4.2. Analysis 
In this comparison, it can be concluded that Pearson’s correlation coefficient 
outperformed other similarities measurement methods in twelve out of fifteen leads. 
We verified that we have obtained the highest similarity among time-series in the 
following leads: VZ, V6, V5, VX, aVR and V1, these were the leads where Pearson’s 
correlation coefficient performed the best. 
 Lastly, the leads where Wavelet Transform KLT based method performed the best, are 
the following: aVF, V5, VX, V3, V6 and V4.  
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4.2.5. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
HEALTHY CONTROLS - II 
In this measurement, the signals that were tested, were collected from different healthy 
individuals. In Figure 4.65, it is represented the cardiac cycles of patient s0311. 
 
Figure 4.65 The cardiac cycles of healthy control s0311, where the x-axis represents the number of cardiac cycles and 
the y-axis the duration of those cycles.  
It was observed that for healthy control s0311 the 29th cardiac cycle was the minimum 
cardiac cycle while the maximum one was the 42th cardiac cycle. The corresponding HRV 
is 12ms.  
So, to measure similarity in these individuals it will be compared the 17th cardiac cycle 
of the s0462 individual with the 42th cardiac cycle of the individual s0311. It will be also 
compared the 14th cardiac cycle of the individual s0462 with the 29th cardiac cycle of the 
individual s0311. The last comparison it will be between the 14th cardiac cycle of the 
individual s0462 and the 42th cardiac cycle of the individual s0311, this will result in 
losing one hundred and thirty-five data points of information. 
4.2.5.1. Results 
The results obtained for the best performed pairs of comparison were between the 14th 
cardiac cycle of the individual s0462 and the 42th cardiac cycle of the individual s0311. 
These are the results below presented. 
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Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 44 83 4.66 
L2 𝑆𝑊𝑇 25 93 4.67 
L3 𝑆𝑊𝑇 47 76 4.68 
V1 𝑆𝑊𝑇 2 83 4.69 
V2 𝑆𝐶𝐶 11 81 4.70 
V3 𝑆𝑊𝑇 10 86 4.71 
V4 𝑆𝑊𝑇 6 89 4.72 
V5 𝑆𝑊𝑇 1 86 4.73 
V6 𝑆𝐶𝐶 41 79 4.74 
Vx 𝑆𝐶𝐶 30 85 4.75 
Vy 𝑆𝐶𝐶 14 80 4.76 
Vz 𝑆𝐶𝐶 7 82 4.77 
aVF 𝑆𝑀𝑖 0,5 50 4.78 
aVL 𝑆𝐶𝐶 59 78 4.79 
aVR 𝑆𝐶𝐶 25 83 4.80 
Table 4-7 Similarity between the 14th cardiac cycle of the s0462 patient with the 42th cardiac cycle of the patient 
s0311. 
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Figure 4.66 L1 lead.  
 
Figure 4.67 L2 lead.  
 
Figure 4.68 L3 lead.  
 
Figure 4.69 V1 lead.  
 
Figure 4.70 V2 lead.  
 
Figure 4.71 V3 lead.  
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Figure 4.72 V4 lead.  
 
Figure 4.73 V5 lead.  
 
Figure 4.74 V6 lead.  
 
Figure 4.75 VX lead.  
 
Figure 4.76 VY lead.  
 
Figure 4.77 VZ lead.  
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Figure 4.78 aVF lead.  
 
Figure 4.79 aVL lead. 
 
Figure 4.80 aVR lead.  
4.2.5.2. Analysis 
In this comparison, it can be concluded that Pearson’s correlation coefficient 
outperformed other similarities measurement methods in eight out of fifteen leads. 
We verified that we have obtained the highest similarity among time-series in the 
following leads: V5, VX, V4, aVR, L1 and VZ, these were the leads where Pearson’s 
correlation coefficient performed the best. 
 Lastly, the leads where Wavelet Transform KLT based method performed the best, were 
the following: L2, V4, V5, V3, V1 and L3. 
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4.3. EXPERIMENT FOR FINDING A PATTERN ON DM PATIENTS WITH 
MYOCARDIAL INFARCTION 
4.3.1. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
PATIENTS WITH DIFFERENT DIAGNOSIS - I 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range. In Figure 4.81, it is represented the cardiac 
cycles of patient s0052. 
 
Figure 4.81 The cardiac cycles of patient s0052, where the x-axis represents the number of cardiac cycles and the y-
axis the duration of those cycles.  
It was observed that for patient s0052 the 1st cardiac cycle was the minimum cardiac cycle 
while the maximum one was the 25th cardiac cycle, so the HRV is 22ms.   
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 25th cardiac cycle of the patient s0052. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 1st cardiac cycle of the patient s0052. 
The last comparison it will be between the 40th cardiac cycle of the patient s0010 and the 
1st cardiac cycle of the patient s0052, this will result in losing two hundred and twenty-
five data points of information. 
4.3.1.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with shorter data lengths best results were attained, for 
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each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝑊𝑇 28 92 4.82 
L2 𝑆𝑊𝑇 76 91 4.83 
L3 𝑆𝐶𝐶 5 49 4.84 
V1 𝑆𝑊𝑇 2 33 4.85 
V2 𝑆𝐶𝐶 2 70 4.86 
V3 𝑆𝑊𝑇 22 93 4.87 
V4 𝑆𝑊𝑇 34 94 4.88 
V5 𝑆𝑊𝑇 86 97 4.89 
V6 𝑆𝑊𝑇 86 95 4.90 
Vx 𝑆𝑊𝑇 38 87 4.91 
Vy 𝑆𝑊𝑇 4 28 4.92 
Vz 𝑆𝑊𝑇 3 49 4.93 
aVF 𝑆𝑊𝑇 7 28 4.94 
aVL 𝑆𝐶𝐶 11 65 4.95 
aVR 𝑆𝑊𝑇 34 67 4.96 
Table 4-8 Similarity between the 13th cardiac cycle of the s0010 patient with the 1st cardiac cycle of the patient s0052. 
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Figure 4.82 L1 lead.  
 
Figure 4.83 L2 lead.  
 
Figure 4.84 L3 lead.  
 
Figure 4.85 V1 lead.  
 
Figure 4.86 V2 lead.  
 
Figure 4.87 V3 lead.  
0 100 200 300 400 500 600 700 800
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
L1
 
 
s0010
s0052
0 100 200 300 400 500 600 700 800
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
L2
 
 
s0010
s0052
0 100 200 300 400 500 600 700 800
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
L3
 
 
s0010
s0052
0 100 200 300 400 500 600 700 800
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
V1
 
 
s0010
s0052
0 100 200 300 400 500 600 700 800
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
V2
 
 
s0010
s0052
0 100 200 300 400 500 600 700 800
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
V3
 
 
s0010
s0052
58 
 
 
Figure 4.88 V4 lead.  
 
Figure 4.89 V5 lead.  
 
Figure 4.90 V6 lead.  
 
Figure 4.91 VX lead.  
 
 
Figure 4.92 VY lead.  
 
Figure 4.93 VZ lead.  
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Figure 4.94 aVF lead. 
 
Figure 4.95 aVL lead. 
 
Figure 4.96 aVR lead.  
4.3.1.2. Analysis 
In this experiment, we can conclude that Wavelet Transform KLT based method 
outperformed other similarities measurement methods in twelve out of fifteen leads.  
We verified that we have obtained the highest similarity among time-series in the 
following leads: V5, V6, V4, V3, L1 and L2, these were the leads where Wavelet 
Transform KLT based method performed the best. 
 Lastly, it will be also considered the leads where Pearson’s correlation coefficient 
performed the best, which were the following: V3, V2, aVL, L1, V4 and L3.  
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4.3.2. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
PATIENTS WITH DIFFERENT DIAGNOSIS - II 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range. In Figure 4.97, it is represented the cardiac 
cycles of patient s0045. 
 
Figure 4.97 The cardiac cycles of patient s0045, where the x-axis represents the number of cardiac cycles and the y-
axis the duration of those cycles.  
It was observed that for patient s0045 the 14th cardiac cycle was the minimum cardiac 
cycle while the maximum one was the 33th cardiac cycle, where the HRV is 12ms. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 33th cardiac cycle of the patient s0045. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 14th cardiac cycle of the patient s0045. 
The last comparison it will be between the 13th cardiac cycle of the patient s0010 and the 
25th cardiac cycle of the patient s0045, this will result in no losses of information. 
4.3.2.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with longer data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity.  
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Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 14 72 4.98 
L2 𝑆𝑊𝑇 37 73 4.99 
L3 𝑆𝐶𝐶 8 60 4.100 
V1 𝑆𝑊𝑇 4 26 4.101 
V2 𝑆𝑊𝑇 20 37 4.102 
V3 𝑆𝑊𝑇 11 48 4.103 
V4 𝑆𝐶𝐶 3 76 4.104 
V5 𝑆𝑊𝑇 20 69 4.105 
V6 𝑆𝑊𝑇 40 68 4.106 
Vx 𝑆𝑊𝑇 27 89 4.107 
Vy 𝑆𝑀𝐴𝐻 2 28 4.108 
Vz 𝑆𝐶𝐶 9 64 4.109 
aVF 𝑆𝑀𝐴𝐻 3 41 4.110 
aVL 𝑆𝐶𝐶 12 70 4.111 
aVR 𝑆𝑊𝑇 21 73 4.112 
Table 4-9 Similarity between the 40th cardiac cycle of the s0010 patient with the 33th cardiac cycle of the patient 
s0045. 
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Figure 4.98 L1 lead.  
 
Figure 4.99 L2 lead.  
 
Figure 4.100 L3 lead.  
 
Figure 4.101 V1 lead.  
 
Figure 4.102 V2 lead.  
 
Figure 4.103 V3 lead.  
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Figure 4.104 V4 lead.  
 
Figure 4.105 V5 lead.  
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Figure 4.106 V6 lead.  
 
Figure 4.107 VX lead.  
 
Figure 4. VY lead.  
 
Figure 4.108 VZ lead.  
 
Figure 4.109 aVF lead.  
 
Figure 4.110 aVL lead.  
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Figure 4.111 aVR lead.  
4.3.2.2. Analysis 
In this experiment, we can conclude that Wavelet Transform KLT based method 
outperformed other similarities measurement methods in eight out of fifteen leads, if we 
calculate its average considering all leads it outperforms the second-best method 
(Pearson’s correlation coefficient) for 10%. 
We verified that we have obtained the highest similarity among time-series in the 
following leads: VX, L2, aVR, V5, V6 and V4, these were the leads where Wavelet 
Transform KLT based method performed the best. 
 Lastly, it will be also considered the leads where Pearson’s correlation coefficient 
performed the best, which were the following: V4, L1, aVL, VZ, VX and L3. 
 
4.3.3. SIMILARITY MEASUREMENTS BETWEEN DIFFERENT 
PATIENTS WITH DIFFERENT DIAGNOSIS - III 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range. In Figure 4.113, it is represented the 
cardiac cycles of patient s0227. 
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Figure 4.112 The cardiac cycles of patient s0227, where the x-axis represents the number of cardiac cycles and the y-
axis the duration of those cycles.  
It was observed that for patient s0227 the 69th cardiac cycle was the minimum cardiac 
cycle while the maximum one was the 31th cardiac cycle, thus the HRV is 5ms. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 31th cardiac cycle of the patient s0227. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 69th cardiac cycle of the patient s0227. 
The last comparison it will be between the 13th cardiac cycle of the patient s0010 and the 
31th cardiac cycle of the patient s0227, this will result in a loss of two hundred and eighty-
one data points. 
4.3.3.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with shorter data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 14 77 4.114 
L2 𝑆𝐶𝐶 19 55 4.115 
L3 𝑆𝐶𝐶 19 67 4.116 
V1 𝑆𝑀𝐴𝐻 9 39 4.117 
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V2 𝑆𝐶𝐶 13 60 4.118 
V3 𝑆𝐶𝐶 15 74 4.119 
V4 𝑆𝐶𝐶 29 83 4.120 
V5 𝑆𝐶𝐶 33 80 4.121 
V6 𝑆𝐶𝐶 9 44 4.122 
Vx 𝑆𝐶𝐶 27 70 4.123 
Vy 𝑆𝐶𝐶 8 43 4.124 
Vz 𝑆𝐶𝐶 15 84 4.125 
aVF 𝑆𝐶𝐶 26 61 4.126 
aVL 𝑆𝐶𝐶 16 73 4.127 
aVR 𝑆𝐶𝐶 9 70 4.128 
Table 4-10 Similarity between the 13th cardiac cycle of the s0010 patient with the 69th cardiac cycle of the patient 
s0227. 
 
 
Figure 4.113 L1 lead.  
 
Figure 4.114 L2 lead.  
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Figure 4.115 L3 lead.  
 
Figure 4.116 V1 lead.  
 
Figure 4.117 V2 lead.  
 
Figure 4.118 V3 lead.  
 
Figure 4.119 V4 lead.  
 
Figure 4.120 V5 lead.  
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Figure 4.121 V6 lead.  
 
Figure 4.122 VX lead.  
 
Figure 4.123 VY lead.  
 
Figure 4.124 VZ lead.  
 
Figure 4.125 aVF lead.  
 
Figure 4.126 aVL lead.  
0 50 100 150 200 250 300 350 400 450
-0.6
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
V6
 
 
s0010
s0227
0 50 100 150 200 250 300 350 400 450
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
VX
 
 
s0010
s0227
0 50 100 150 200 250 300 350 400 450
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
VY
 
 
s0010
s0227
0 50 100 150 200 250 300 350 400 450
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
VZ
 
 
s0010
s0227
0 50 100 150 200 250 300 350 400 450
-0.5
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
aVF
 
 
s0010
s0227
0 50 100 150 200 250 300 350 400 450
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
0.6
aVL
 
 
s0010
s0227
70 
 
 
Figure 4.127 aVR lead. 
4.3.3.2. Analysis 
In this experiment, we can conclude that Pearson’s correlation coefficient outperformed 
other similarities measurement methods in fourteen out of fifteen leads.  
We verified that we have obtained the highest similarity among time-series in the 
following leads: VZ, V4, V5, L1, V3 and aVL, these were the leads where Pearson’s 
correlation coefficient performed the best. 
 Lastly, it will be also considered the leads where Wavelet Trasnform KLT based method 
performed the best, which were the following: aVR, VZ, V4, V5, V3 and L1. 
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4.3.4. SIMILARITY MEASUREMENTS BETWEEN A PATIENT AND A 
HEALTHY CONTROL - I 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range. In Figure 4.49a, it is represented the 
cardiac cycles of healthy control s0462. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 17th cardiac cycle of the patient s0462. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 14th cardiac cycle of the patient s0462. 
The last comparison it will be between the 40th cardiac cycle of the patient s0010 and the 
14th cardiac cycle of the patient s0462, this will result in a loss of one hundred and six 
data points. 
4.3.4.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with shorter data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. 
Lead Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 12 68 4.129 
L2 𝑆𝑊𝑇 32 56 4.130 
L3 𝑆𝑀𝐴𝐻 4 14 4.131 
V1 𝑆𝑀𝐴𝐻 6 34 4.132 
V2 𝑆𝐶𝐶 13 70 4.133 
V3 𝑆𝐶𝐶 7 81 4.134 
V4 𝑆𝑊𝑇 34 99 4.135 
V5 𝑆𝑊𝑇 80 97 4.136 
V6 𝑆𝑊𝑇 74 89 4.137 
Vx 𝑆𝑊𝑇 32 84 4.138 
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Vy 𝑆𝑀𝐴𝐻 1 18 4.139 
Vz 𝑆𝐶𝐶 2 59 4.140 
aVF 𝑆𝑊𝑇 4 17 4.141 
aVL 𝑆𝐶𝐶 8 49 4.142 
Table 4-11 Similarity between the 13th cardiac cycle of the s0010 patient with the 14th cardiac cycle of the patient 
s0462. 
 
Figure 4.128 L1 lead.  
 
Figure 4.129 L2 lead.  
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Figure 4.130 L3 lead.  
 
Figure 4.131 V1 lead.  
 
Figure 4.132 V2 lead.  
 
Figure 4.133 V3 lead.  
 
Figure 4.134 V4 lead.  
 
Figure 4.135 V5 lead.  
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Figure 4.136 V6 lead.  
 
Figure 4.137 VX lead.  
 
Figure 4.138 VY lead.  
 
Figure 4.139 VZ lead.  
 
Figure 4.140 aVF lead.  
 
Figure 4.141 aVL lead.  
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Figure 4.142 aVR lead.  
4.3.4.2. Analysis 
In this experiment, we can conclude that Wavelet Transform KLT based method 
outperformed other similarities measurement methods in seven out of fifteen leads, if we 
calculate its average considering all leads it outperforms the second-best method 
(Pearson’s correlation coefficient) for 17%. 
We verified that we have obtained the highest similarity among time-series in the 
following leads: V4, V5, V6, VX, V3 and VZ, these were the leads where Wavelet 
Transform KLT based method performed the best. 
 Lastly, it will be also considered the leads where Pearson’s correlation coefficient 
performed the best, which were the following: V3, V2, L1, V4, VZ and VX. 
4.3.5. SIMILARITY MEASUREMENTS BETWEEN A PATIENT AND A 
HEALTHY CONTROL - II 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range. In Figure 4.49b, it is represented the 
cardiac cycles of healthy control s0303.  
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 6th cardiac cycle of the patient s0303. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 12th cardiac cycle of the patient s0303. 
The last comparison it will be between the 40th cardiac cycle of the patient s0010 and the 
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16th cardiac cycle of the patient s0303, this will result in a lossless comparison in terms 
of data points. 
4.3.5.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with shorter data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝐶𝐶 16 57 4.144 
L2 𝑆𝑊𝑇 53 89 4.145 
L3 𝑆𝑀𝐴𝐻 1 15 4.146 
V1 𝑆𝐶𝐶 1 26 4.147 
V2 𝑆𝐶𝐶 2 32 4.148 
V3 𝑆𝐶𝐶 24 60 4.149 
V4 𝑆𝐶𝐶 32 76 4.150 
V5 𝑆𝑊𝑇 39 76 4.151 
V6 𝑆𝑊𝑇 32 50 4.152 
Vx 𝑆𝑊𝑇 16 73 4.153 
Vy 𝑆𝑀𝑖 1 20 4.154 
Vz 𝑆𝐶𝐶 39 76 4.155 
aVF 𝑆𝑀𝑖 3 13 4.156 
aVL 𝑆𝐶𝐶 12 47 4.157 
aVR 𝑆𝑊𝑇 54 87 4.158 
Table 4-12 Similarity between the 13th cardiac cycle of the s0010 patient with the 12th cardiac cycle of the patient 
s0303. 
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Figure 4.143 L1 lead.  
 
Figure 4.144 L2 lead.  
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Figure 4.145 L3 lead.  
 
Figure 4.146 V1 lead.  
 
Figure 4.147 V2 lead.  
 
Figure 4.148 V3 lead.  
 
Figure 4.149 V4 lead.  
 
Figure 4.150 V5 lead.  
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Figure 4.151 V6 lead.  
 
Figure 4.152 VX lead.  
 
Figure 4.153 VY lead.  
 
Figure 4.154 VZ lead.  
 
Figure 4.155 aVF lead.  
 
Figure 4.156 aVL lead.  
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Figure 4.157 aVR lead.  
4.3.5.2. Analysis 
In this experiment, we can conclude that both methods (Wavelet Transform KLT based 
and Pearson’s correlation coefficient) performed evenly. Pearson’s correlation coefficient 
performed better in seven out of fifteen leads, but if we calculate the average for both 
methods considering all leads the Wavelet Transform KLT based performs 8% better.  
We verified that we have obtained the highest similarity among time-series in the 
following leads: L2, aVR, V5, VX, V6 and V4, these were the leads where Wavelet 
Transform KLT based method performed the best. 
The leads where Pearson’s correlation coefficient performed the best, which were the 
following: VZ, V4, V3, VX, L1 and aVL. 
4.3.6. SIMILARITY MEASUREMENTS BETWEEN A PATIENT AND A 
HEALTHY CONTROL - III 
In this measurement, the cardiac signals that were tested, were collected from a cohort 
with different diagnosis, gender and age range.  
In Figure 4.65, it is represented the cardiac cycles of healthy control s0311. 
So, to measure similarity in these patients it will be compared the 40th cardiac cycle of 
the s0010 patient with the 42th cardiac cycle of the patient s0311. It will be also compared 
the 13th cardiac cycle of the patient s0010 with the 29th cardiac cycle of the patient s0311. 
The last comparison it will be between the 17th cardiac cycle of the patient s0010 and the 
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41th cardiac cycle of the patient s0311, this will result in a lossless comparison in terms 
of data points. 
4.3.6.1. Results 
Since among these three comparisons it was observed that when comparing the time-
series related to the cardiac cycles with closer data lengths best results were attained, for 
each ECG lead will only be presented the best performed results for the sake of thesis’ 
simplicity. 
Lead 
Best performed 
method 
Exceeding the other 
methods performance by 
(%) 
Similarity 
measure 
achieved (%) 
Figure 
L1 𝑆𝑊𝑇 17 84 4.159 
L2 𝑆𝑊𝑇 50 72 4.160 
L3 𝑆𝐶𝐶 13 66 4.161 
V1 𝑆𝐶𝐶 3 39 4.162 
V2 𝑆𝐶𝐶 2 75 4.163 
V3 𝑆𝑊𝑇 18 92 4.164 
V4 𝑆𝑊𝑇 23 95 4.165 
V5 𝑆𝑊𝑇 58 95 4.166 
V6 𝑆𝑊𝑇 13 33 4.167 
Vx 𝑆𝐶𝐶 4 56 4.168 
Vy 𝑆𝑊𝑇 0,5 16 4.169 
Vz 𝑆𝐶𝐶 15 86 4.170 
aVF 𝑆𝐶𝐶 15 43 4.171 
aVL 𝑆𝐶𝐶 11 68 4.172 
aVR 𝑆𝑊𝑇 48 95 4.173 
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Table 4-13 Similarity between the 17th cardiac cycle of the s0010 patient with the 31th cardiac cycle of the patient 
s0311. 
 
Figure 4.158 L1 lead.  
 
Figure 4.159 L2 lead.  
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Figure 4.160 L3 lead.  
 
Figure 4.161 V1 lead.  
 
Figure 4.162 V2 lead.  
 
Figure 4.163 V3 lead.  
 
Figure 4.164 V4 lead.  
 
Figure 4.165 V5 lead.  
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Figure 4.166 V6 lead.  
 
Figure 4.167 VX lead.  
 
Figure 4.168 VY lead.  
 
Figure 4.169 VZ lead.  
 
Figure 4.170 aVF lead.  
 
Figure 4.171 aVL lead.  
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Figure 4.172 aVR lead.  
4.3.6.2. Analysis 
In this experiment, we can conclude that both methods (Wavelet Transform KLT based 
and Pearson’s correlation coefficient) performed evenly. Wavelet Transform KLT based 
performed better in eight out of fifteen leads, also if we calculate the average for both 
methods considering all leads the Wavelet Transform KLT based performs 12% better.  
We verified that we have obtained the highest similarity among time-series in the 
following leads: V5, V4, aVR, V3, L1 and V2, these were the leads where Wavelet 
Transform KLT based method performed the best. 
The leads where Pearson’s correlation coefficient performed the best, which were the 
following: VZ, V3, V2, aVL, L1 and L3. 
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5. CONCLUDING REMARKS 
5.1. CONCLUSION 
In this thesis, we can conclude from the first experience (finding the most representative 
ECG leads in terms of similarity values within cohorts) that the best methods for 
measuring similarity among time-series from the cohorts with patients with the same 
diagnosis would be Pearson’s correlation coefficient immediately followed by the 
Wavelet Transform KLT based methods. We also concluded that statistically speaking 
the more consistent leads for this effect would be L1, V4, VZ and aVL for Pearson’s 
correlation coefficient and V3, V4, VX and aVF for Wavelet Transform KLT based 
method. 
On the second experience, we have measured the similarity among different cohorts with 
patients with different diagnosis, age range and gender. Using Pearson’s correlation 
coefficient and Wavelet Transform KLT based method and the above referred seven 
leads, the aim was to find a pattern among DM patients with myocardial infarction. With 
this methodology we could not find a common pattern, so an average of the performance 
obtained on the six best performed leads was considered, as well as, an average of the 
performance obtained for all leads. Analysing all the measurements for Pearson’s 
correlation coefficient we have constructed Table 5-1:  
Cohort4 Considering all leads Considering the six 
best leads 
Considering the four 
more consistent leads 
1.1 100% 100% 100% 
1.2 88% 93% 91% 
2.1 47% 73% 70% 
2.2 49% 73% 64% 
3.1 36% 63% 58% 
3.2 42% 67% 71% 
3.3 65% 79% 79% 
4.1 34% 66% 60% 
                                                 
4 Cohorts are described in detail, in section 4.1. 
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4.2 33% 62% 64% 
4.3 47% 75% 61% 
Table 5-1  Averaging the results of the measurements considering Pearson’s correlation coefficient in different leads. 
Analysing this table, we can conclude that the best methodology should be using the six 
best leads, where there are still results that are unexpected. If we look to cohort 3.3, where 
the patient has arterial hypertension we can explain the higher similarity in that 
comparison due to the amount of data that was lost through the pre-processing. The 
template signal lost 291 data points which is 41% of its signal, where it might be a loss 
of valuable data points. But this explanation cannot explain the result in cohort 4.3 which 
is a comparison with a healthy control. To explain these latter results a further study was 
made, and it was found that there is valuable data in T-waves when it comes to DM 
patients [28], which are often lost due to centring the signals by QRS complex.  
Analysing all the measurements for Wavelet Transform KLT based we have constructed 
Table 5-2:  
Cohort 
Considering all 
leads 
Considering the 
six best leads 
Considering the 
four more 
consistent leads 
1.1 100% 100% 100% 
1.2 47% 74% 80% 
2.1 46% 65% 37% 
2.2 52% 77% 61% 
3.1 65% 94% 75% 
3.2 52% 73% 58% 
3.3 31% 42% 30% 
4.1 51% 83% 69% 
4.2 41% 70% 40% 
4.3 59% 89% 66% 
Table 5-2  Averaging the results of the measurements considering Wavelet Transform based method in different leads. 
If we analyse how Wavelet Transform KLT based method works, which focusses on the 
shape of the signal, the result on the cohort in 3.3 is due to the loss of data on template 
signal during pre-processing. We can also see that we achieved a better measurement in 
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3.1 which is a patient with myocardial infarction, diabetes mellitus and hyperuricemia 
than in the measurement between the same patient, which is as well not expected, but 
once again, the loss of data might be the explanation for this result, since it was lost 261 
data points on the signal we wanted to compare with the template, this is a loss of 27% of 
the signal. 
Besides the conclusions of the experiments, the data obtained is also valuable to 
emphasize some conclusions from other researches. Firstly, by measuring similarity 
among the same patient we can conclude that Wavelet Transform KLT based method is 
more sensitive to small variations on the signal than Pearson’s correlation coefficient. On 
the other hand, Pearson’s correlation coefficient is more robust (less affected by baseline 
variations) [23]. In this situation, we can say that Pearson’s correlation coefficient would 
be the desirable choice for finding a pattern, even so more experiments needed to be tested 
and a larger database should be considered. 
In overall, we can also conclude that for comparisons between patients with the same 
diagnosis Pearson’s correlation coefficient will outperforms Wavelet transform based 
method (cohort 2.2 is an exception, where the difference between measurements is 
approximately 5%). However, when comparing patients with different diagnosis, we 
should consider as the best performed the method which presents less similarity since the 
pathologies are different. In this situation the Pearson’s correlation coefficient is still the 
method to consider however cohort 3.3 is an exception (above explained). 
Lastly, we can emphasize that low HRV is associated with CVDs and increasing age, as 
can be confirmed by other researchers [29]. If we check the results of HRV obtained along 
this research we verified that the healthy controls have higher HRV than the CVD’s 
patients considered, where the healthy control s0311 is the exception, this might be also 
explained due to the age of this particular patient (79 years old) [17]. 
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5.2. FUTURE WORK 
For future work, it would be desirable to do the same experiments changing the procedure 
on centring ECG signals by QRS complex. Instead, we would align the ECG’s time-series 
in a way that we would not loose data points in QRS complex neither in T-wave.  
Another thing to think about, would be time-scaling. In signals which QRS complex have 
the same shape but its duration varies (in order of 50-100 ms or higher), this 
implementation might be useful to improve the performance of similarity measurements. 
Lastly, as we know biomedical signal’s characteristics varies cycle to cycle, even if it is 
just a little, where similarity 1 is literally impossible to achieve, so it would be interesting 
in replacing the scale [0, 1] into a more realistic one. For instance, we could measure the 
template’s cardiac cycle one with another in ideal conditions (comparing different cardiac 
signals from the template), and our real maximum would be the worst measurement. 
 
 
 
  
90 
 
REFERENCES 
 
[1]  World Health Organization, “WHO - Diabetes mellitus,” 2017. 
[Online]. Available: http://www.who.int/mediacentre/factsheets/fs138/en/. 
[Accessed 03 09 2017]. 
[2]  World Health Organization - Regional Office for Europe, 
“WHO/Europe - Diabetes,” 2017. [Online]. Available: 
http://www.euro.who.int/en/health-topics/noncommunicable-
diseases/diabetes . [Accessed 03 09 2017]. 
[3]  World Health Organization, “WHO - 10 facts on diabetes,” 2017. 
[Online]. Available: http://www.who.int/features/factfiles/diabetes/en/ . 
[Accessed 03 09 2017]. 
[4]  T.-c. Fu, “A review on time series data mining,” Engineering 
Applications of Artificial Intelligence, vol. 24, pp. 164-81, 2011.  
[5]  U.S Department of Health & Human Services, “Your Heart's Electrical 
System,” 17 11 2011. [Online]. Available: 
https://www.nhlbi.nih.gov/health/health-topics/topics/hhw/electrical. 
[Accessed 23 09 2017]. 
[6]  R. M. Rangayyan, BIOMEDICAL SIGNAL ANALISYS A Case-Study 
Approach, Calgary, Alberta, Canada: John Wiley & Sons,Inc, 2002.  
[7]  “ECG timeline - History of electrocardiography,” 2009. [Online]. 
Available: https://ecglibrary.com/ecghist.html. [Accessed 23 9 2017]. 
[8]  M. A. a. J. Lindsay, “A brief revier: history to understand fundamentals 
of electrocardiography,” 30 04 2012. [Online]. Available: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714093/. [Accessed 23 09 
2017]. 
[9]  “Electrocardiogram (EKG or ECG),” [Online]. Available: 
http://www.webmd.com/heart/ekg-components-and-intervals. [Accessed 30 
09 2017]. 
[10]  R. M. a. B. Birchler, “ECG Measurement and Analysis,” p. 17, 24 2 
2014.  
91 
 
[11]  “CardioSecur - ECG Lead Systems,” [Online]. Available: 
https://www.cardiosecur.com/en/your-heart/specialty-articles/ecg-lead-
systems/. [Accessed 24 9 2017]. 
[12]  “Frank vectorcardiographic system from standard 12 lead ECG: An 
effort to enhance cardiovascular diagnosis,” 23 12 2015. [Online]. Available: 
https://www.ncbi.nlm.nih.gov/pubmed/26806119. [Accessed 24 09 2017]. 
[13]  “Physionet,” [Online]. Available: 
https://www.physionet.org/physiobank/database/ptbdb/. [Accessed 24 9 
2017]. 
[14]  “Vectorcardiographic Lead Systems,” [Online]. Available: 
http://www.bem.fi/book/16/16.htm. [Accessed 24 9 2017]. 
[15]  “Heart Rate variability vs Heart rate,” [Online]. Available: 
https://hrvcourse.com/heart-rate-variability-vs-heart-rate/. [Accessed 24 9 
2017]. 
[16]  S. M. H. H. a. A. M. M. Nikhil Narayanaswamy, “Assessment of Risk 
Factor for Cardiovascular Disease Using Heart Rate Variability in 
Postmenopausal Women: A Comparative Study between Urban and Rural 
Indian Women,” p. 6, 18 6 2013.  
[17]  K. B. G. R. d. M. C. A. S. J. W. J. S. M. F. R. R. a. O. M. D. Stefanie 
Hillebrand, “Heart rate variability and first cardiovascular event in 
populations without known cardiovascular disease: meta-analysis and dose–
response meta-regression,” p. 8, 30 1 2013.  
[18]  P. Esling and C. Agon, “Time-Series Data Mining,” ACM Computing 
Surveys, vol. 45, pp. 12-34, 11 2012.  
[19]  Yi-Leh Wu, D. Agrawal and A. El Abbadi, A comparison of DFT and 
DWT based similarity search in time-series databases, Santa Barbara, 
California.  
[20]  A. Kianimajd, M. G. Ruano, P. Carvalho, J. Henriques, T. Rocha and 
S. Paredes, Comparison of different methods of measuring similarity in 
physiologic time series, Faro, 2017.  
92 
 
[21]  C. Cassisi, P. Montalto, M. Aliotta, A. Cannata and A. Pulvirenti, 
“Similarity Measures and Dimensionality Reduction Techniques for Time 
Series Data Mining,” Catania, Itália, InTech , 2012, pp. 71-96. 
[22]  “Pearson's Correlation: Definition,” [Online]. Available: 
http://www.statisticshowto.com/what-is-the-pearson-correlation-coefficient/. 
[Accessed 24 09 2017]. 
[23]  T. Rocha, S. . Paredes, P. Carvalho and J. Henriques, “An Efficient 
Strategy for Evaluating Similarity between Time Series based on Wavelet / 
Karhunen-Loève Transforms,” Int. Conf. of the IEEE Engineering in 
Medicine and Biology, pp. 6216-6219, 2012.  
[24]  Engineering Productivity Tools Ltd., “Definition of DFT and Inverse 
DFT (IDFT),” 1999. [Online]. Available: 
http://www.engineeringproductivitytools.com/stuff/T0001/PT01.HTM. 
[Accessed 14 09 2017]. 
[25]  “The Fast Lifting Wavelet Transform,” [Online]. Available: 
http://www.polyvalens.com/blog/wavelets/theory/#7.+The+scaling+func-
tion+%5B7%5D . [Accessed 14 09 2017]. 
[26]  “Mathworks,” [Online]. Available: 
http://www.mathworks.com/help/wavelet/ug/wavelet-
packets.html?refresh=true&s_tid=gn_loc_drop. [Accessed 24 9 2017]. 
[27]  “Mathworks,” [Online]. Available: 
https://www.mathworks.com/products/matlab.html. [Accessed 24 9 2017]. 
[28]  M. Shlomo Stern and M. Samuel Sclarowsky, “The ECG in Diabetes 
Mellitus,” Clinician Update, p. 5, 20 10 2009.  
[29]  M. M. Reardon M, “Changes in heart rate variability with age.,” 19 11 
1996. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/8945057. 
[Accessed 1 09 2017]. 
 
 
´ 
93 
 
APPENDIX 
I – Similarity Measurements between the same patient 
 
 
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média total 
 
CC 
 
 
 
WT 
 
 
s0014_L1 0,09 0,22 0,53 0,51 0,64 0,94 0,06 0,70  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,67 
s0014_VY 0,74 s0014_V1 0,21 
s0014_L2 0,07 0,11 0,48 0,41 0,46 0,86 0,07 0,60 s0014_aVR 0,80 s0014_VY 0,22 
s0014_L3 0,16 0,25 0,61 0,78 0,41 0,94 0,18 0,78 s0014_V6 0,81 s0014_V6 0,27 
s0014_V1 0,08 0,01 0,27 0,62 0,21 0,86 0,07 0,59 s0014_L2 0,86 s0014_V2 0,32 
s0014_V2 0,11 0,06 0,43 0,65 0,32 0,88 0,12 0,65 s0014_V1 0,86 s0014_VZ 0,33 
s0014_V3 0,27 0,68 0,61 0,83 0,70 0,93 0,17 0,82 s0014_VZ 0,86 s0014_V5 0,35 
s0014_V4 0,34 0,85 0,60 0,84 0,76 0,92 0,27 0,87 s0014_V2 0,88 s0014_L3 0,41 
s0014_V5 0,09 0,09 0,50 0,56 0,35 0,90 0,09 0,65 s0014_VX 0,89 s0014_L2 0,46 
s0014_V6 0,05 0,00 0,43 0,51 0,27 0,81 0,06 0,53 s0014_V5 0,90 s0014_aVR 0,57 
s0014_VX 0,22 0,50 0,54 0,75 0,53 0,89 0,17 0,73 s0014_aVF 0,90 s0014_aVL 0,63 
s0014_VY 0,00 0,00 0,23 0,21 0,22 0,74 0,00 0,40 s0014_V4 0,92 s0014_L1 0,64 
s0014_VZ 0,03 0,02 0,42 0,27 0,33 0,86 0,03 0,54 s0014_V3 0,93 s0014_V3 0,70 
s0014_aVF 0,21 0,33 0,59 0,79 0,86 0,90 0,14 0,85 s0014_L3 0,94 s0014_V4 0,76 
s0014_aVL 0,22 0,36 0,58 0,84 0,44 0,96 0,20 0,79 s0014_L1 0,94 s0014_aVF 0,86 
s0014_aVR 0,02 0,01 0,32 0,07 0,57 0,80 0,01 0,56 s0014_aVL 0,96 s0014_VX 0,87 
     0,47 0,88     0,93  0,74 
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II – Similarity Measurements between different patients with the same diagnosis - I 
  
ED 
 
DT
W 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média 
total 
 
CC 
 
WT 
s0088_L1 0,04 0,00 0,28 0,28 0,78 0,72 0,05 0,60  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,44 
s0088_L2 0,00 s0088_V4 0,16 
s0088_L2 0,02 0,00 0,23 0,12 0,47 0,00 0,02 0,27 s0088_V1 0,00 s0088_V3 0,17 
s0088_L3 0,11 0,13 0,46 0,70 0,56 0,84 0,19 0,70 s0088_V6 0,13 s0088_VY 0,25 
s0088_V1 0,00 0,00 0,08 0,10 0,41 0,00 0,00 0,20 s0088_aVR 0,27 s0088_V2 0,26 
s0088_V2 0,01 0,00 0,13 0,20 0,26 0,28 0,01 0,25 s0088_V2 0,28 s0088_VZ 0,38 
s0088_V3 0,05 0,01 0,20 0,37 0,17 0,51 0,07 0,36 s0088_VY 0,45 s0088_V5 0,39 
s0088_V4 0,10 0,20 0,29 0,45 0,16 0,58 0,12 0,44 s0088_VX 0,46 s0088_V1 0,41 
s0088_V5 0,05 0,06 0,38 0,43 0,39 0,55 0,04 0,46 s0088_V3 0,51 s0088_V6 0,43 
s0088_V6 0,01 0,00 0,27 0,20 0,43 0,13 0,01 0,30 s0088_V5 0,55 s0088_L2 0,47 
s0088_VX 0,03 0,00 0,23 0,19 0,59 0,46 0,03 0,43 s0088_V4 0,58 s0088_aVF 0,55 
s0088_VY 0,02 0,00 0,25 0,39 0,25 0,45 0,02 0,36 s0088_VZ 0,65 s0088_L3 0,56 
s0088_VZ 0,06 0,24 0,31 0,42 0,38 0,65 0,04 0,48 s0088_L1 0,72 s0088_VX 0,59 
s0088_aVF 0,09 0,35 0,46 0,58 0,55 0,74 0,14 0,62 s0088_aVF 0,74 s0088_aVL 0,65 
s0088_aVL 0,07 0,01 0,34 0,58 0,65 0,84 0,12 0,69 s0088_aVL 0,84 s0088_L1 0,78 
s0088_aVR 0,02 0,00 0,23 0,07 0,79 0,27 0,02 0,43 s0088_L3 0,84 s0088_aVR 0,79 
     0,46 0,47     0,73  0,65 
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III – Similarity Measurements between different patients with the same diagnosis - II 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média 
total 
 
CC 
 
WT 
s0004_L1 0,04 0,24 0,24 0,31 0,27 0,59 0,06 0,39  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,48 
s0004_aVF 0,19 s0004_L3 0,07 
s0004_L2 0,04 0,02 0,24 0,23 0,78 0,33 0,03 0,45 s0004_V1 0,21 s0004_aVF 0,16 
s0004_L3 0,03 0,11 0,14 0,38 0,07 0,29 0,04 0,27 s0004_V6 0,22 s0004_L1 0,27 
s0004_V1 0,02 0,01 0,12 0,34 0,35 0,21 0,03 0,30 s0004_L3 0,29 s0004_VY 0,30 
s0004_V2 0,19 0,33 0,53 0,78 0,78 0,88 0,11 0,81 s0004_VY 0,33 s0004_aVL 0,30 
s0004_V3 0,27 0,72 0,63 0,83 0,77 0,91 0,23 0,84 s0004_L2 0,33 s0004_V1 0,35 
s0004_V4 0,17 0,51 0,48 0,63 0,87 0,78 0,14 0,76 s0004_V5 0,37 s0004_V5 0,54 
s0004_V5 0,03 0,02 0,29 0,32 0,54 0,37 0,03 0,41 s0004_aVR 0,52 s0004_aVR 0,58 
s0004_V6 0,02 0,03 0,29 0,29 0,61 0,22 0,02 0,40 s0004_VX 0,54 s0004_V6 0,61 
s0004_VX 0,05 0,08 0,24 0,31 0,64 0,54 0,04 0,49 s0004_VZ 0,58 s0004_VX 0,64 
s0004_VY 0,01 0,00 0,13 0,35 0,30 0,33 0,02 0,33 s0004_L1 0,59 s0004_V3 0,77 
s0004_VZ 0,06 0,07 0,35 0,42 0,80 0,58 0,08 0,60 s0004_aVL 0,63 s0004_L2 0,78 
s0004_aVF 0,03 0,02 0,14 0,30 0,16 0,19 0,05 0,22 s0004_V4 0,78 s0004_V2 0,78 
s0004_aVL 0,05 0,40 0,27 0,54 0,30 0,63 0,05 0,49 s0004_V2 0,88 s0004_VZ 0,80 
s0004_aVR 0,03 0,00 0,27 0,15 0,58 0,52 0,03 0,46 s0004_V3 0,91 s0004_V4 0,87 
     0,52 0,49     0,73  0,77 
96 
 
IV – Similarity Measurements between different Healthy Controls - I 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
 
Média 
total 
 
CC 
 
WT 
s0303_L1 0,01 0,00 0,32 0,00 0,29 0,77 0,01 0,46  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,56 
s0303_aVL 0,00 s0303_aVR 0,18 
s0303_L2 0,12 0,25 0,45 0,21 0,31 0,81 0,11 0,53 s0303_V3 0,60 s0303_VY 0,21 
s0303_L3 0,07 0,10 0,44 0,09 0,44 0,62 0,06 0,50 s0303_L3 0,62 s0303_L1 0,29 
s0303_V1 0,27 0,60 0,58 0,67 0,37 0,82 0,18 0,69 s0303_V2 0,72 s0303_L2 0,31 
s0303_V2 0,14 0,07 0,43 0,54 0,42 0,72 0,17 0,57 s0303_V4 0,76 s0303_VZ 0,35 
s0303_V3 0,03 0,00 0,28 0,23 0,57 0,60 0,04 0,48 s0303_VY 0,76 s0303_V1 0,37 
s0303_V4 0,08 0,03 0,32 0,50 0,44 0,76 0,08 0,57 s0303_aVF 0,77 s0303_aVL 0,39 
s0303_V5 0,08 0,17 0,40 0,51 0,66 0,86 0,09 0,68 s0303_L1 0,77 s0303_V2 0,42 
s0303_V6 0,14 0,34 0,46 0,64 0,50 0,87 0,14 0,67 s0303_L2 0,81 s0303_L3 0,44 
s0303_VX 0,06 0,13 0,36 0,48 0,61 0,84 0,05 0,64 s0303_V1 0,82 s0303_V4 0,44 
s0303_VY 0,16 0,07 0,43 0,41 0,21 0,76 0,19 0,53 s0303_aVR 0,82 s0303_V6 0,50 
s0303_VZ 0,21 0,36 0,49 0,73 0,35 0,94 0,18 0,72 s0303_VX 0,84 s0303_V3 0,57 
s0303_aVF 0,21 0,57 0,54 0,49 0,80 0,77 0,18 0,70 s0303_V5 0,86 s0303_VX 0,61 
s0303_aVL 0,00 0,00 0,24 0,00 0,39 0,00 0,01 0,21 s0303_V6 0,87 s0303_V5 0,66 
s0303_aVR 0,03 0,01 0,43 0,01 0,18 0,82 0,03 0,48 s0303_VZ 0,94 s0303_aVF 0,80 
     0,44 0,73     0,86  0,60 
97 
 
V – Similarity Measurements between different Healthy Controls - II 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média 
total 
 
CC 
 
WT 
s0311_L1 0,15 0,13 0,32 0,17 0,39 0,83 0,15 0,51  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,63 
s0311_L3 0,29 s0311_aVL 0,01 
s0311_L2 0,32 0,68 0,65 0,66 0,93 0,80 0,33 0,74 s0311_aVF 0,50 s0311_V6 0,32 
s0311_L3 0,05 0,01 0,25 0,03 0,76 0,29 0,05 0,44 s0311_V3 0,76 s0311_aVF 0,33 
s0311_V1 0,19 0,52 0,55 0,56 0,83 0,81 0,17 0,73 s0311_aVL 0,78 s0311_L1 0,39 
s0311_V2 0,22 0,33 0,59 0,70 0,68 0,81 0,19 0,73 s0311_V6 0,79 s0311_VX 0,40 
s0311_V3 0,08 0,01 0,38 0,53 0,86 0,76 0,06 0,72 s0311_L2 0,80 s0311_VY 0,51 
s0311_V4 0,15 0,11 0,45 0,70 0,89 0,83 0,11 0,81 s0311_VY 0,80 s0311_aVR 0,58 
s0311_V5 0,19 0,28 0,50 0,76 0,86 0,85 0,15 0,83 s0311_V2 0,81 s0311_VZ 0,65 
s0311_V6 0,02 0,05 0,38 0,15 0,32 0,79 0,01 0,49 s0311_V1 0,81 s0311_V2 0,68 
s0311_VX 0,08 0,20 0,51 0,55 0,40 0,85 0,07 0,63 s0311_VZ 0,82 s0311_L3 0,76 
s0311_VY 0,25 0,59 0,66 0,62 0,51 0,80 0,20 0,69 s0311_L1 0,83 s0311_V1 0,83 
s0311_VZ 0,15 0,09 0,52 0,60 0,65 0,82 0,18 0,69 s0311_aVR 0,83 s0311_V3 0,86 
s0311_aVF 0,16 0,15 0,50 0,35 0,33 0,50 0,15 0,45 s0311_V4 0,83 s0311_V5 0,86 
s0311_aVL 0,07 0,01 0,19 0,00 0,01 0,78 0,08 0,35 s0311_VX 0,85 s0311_V4 0,89 
s0311_aVR 0,25 0,51 0,52 0,48 0,58 0,83 0,22 0,64 s0311_V5 0,85 s0311_L2 0,93 
     0,60 0,76     0,83  0,86 
98 
 
VI - Similarity Measurements between different patients with different diagnosis - I 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
 
Média total 
 
CC 
 
WT 
s0052_L1 0,09 0,02 0,35 0,47 0,92 0,64 0,08 0,68  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,45 
s0052_L2 0,00 s0052_L3 0,25 
s0052_L2 0,02 0,00 0,15 0,11 0,91 0,00 0,02 0,39 s0052_V6 0,00 s0052_VY 0,28 
s0052_L3 0,03 0,00 0,31 0,44 0,25 0,49 0,04 0,42 s0052_VY 0,00 s0052_aVF 0,28 
s0052_V1 0,02 0,02 0,18 0,31 0,33 0,25 0,03 0,30 s0052_aVF 0,00 s0052_V1 0,33 
s0052_V2 0,06 0,35 0,39 0,48 0,68 0,70 0,06 0,62 s0052_V5 0,11 s0052_aVL 0,36 
s0052_V3 0,07 0,26 0,41 0,48 0,93 0,71 0,06 0,71 s0052_V1 0,25 s0052_VZ 0,49 
s0052_V4 0,05 0,01 0,25 0,28 0,94 0,60 0,05 0,61 s0052_aVR 0,33 s0052_aVR 0,67 
s0052_V5 0,01 0,00 0,11 0,09 0,97 0,11 0,01 0,39 s0052_VZ 0,46 s0052_V2 0,68 
s0052_V6 0,00 0,00 0,09 0,06 0,95 0,00 0,00 0,37 s0052_VX 0,49 s0052_VX 0,87 
s0052_VX 0,04 0,00 0,25 0,29 0,87 0,49 0,04 0,55 s0052_L3 0,49 s0052_L2 0,91 
s0052_VY 0,01 0,00 0,14 0,24 0,28 0,00 0,01 0,22 s0052_V4 0,60 s0052_L1 0,92 
s0052_VZ 0,04 0,02 0,29 0,37 0,49 0,46 0,08 0,44 s0052_L1 0,64 s0052_V3 0,93 
s0052_aVF 0,02 0,00 0,18 0,21 0,28 0,00 0,02 0,22 s0052_aVL 0,65 s0052_V4 0,94 
s0052_aVL 0,06 0,00 0,35 0,54 0,36 0,65 0,07 0,51 s0052_V2 0,70 s0052_V6 0,95 
s0052_aVR 0,05 0,00 0,24 0,17 0,67 0,33 0,05 0,41 s0052_V3 0,71 s0052_V5 0,97 
     0,65 0,36     0,63  0,94 
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VII - Similarity Measurements between different patients with different diagnosis - II 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
 
Média total 
 
CC 
 
WT 
s0045_L1 0,11 0,12 0,34 0,56 0,58 0,72 0,12 0,62  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,46 
s0045_VY 0,00 s0045_L3 0,25 
s0045_L2 0,05 0,20 0,36 0,32 0,73 0,19 0,06 0,47 s0045_V1 0,07 s0045_VY 0,26 
s0045_L3 0,05 0,12 0,39 0,52 0,25 0,60 0,07 0,51 s0045_V2 0,11 s0045_V1 0,26 
s0045_V1 0,01 0,00 0,16 0,22 0,26 0,07 0,01 0,22 s0045_V6 0,14 s0045_aVF 0,30 
s0045_V2 0,01 0,00 0,16 0,17 0,37 0,11 0,01 0,23 s0045_L2 0,19 s0045_V2 0,37 
s0045_V3 0,04 0,05 0,27 0,34 0,48 0,37 0,04 0,40 s0045_aVF 0,36 s0045_aV
L 
0,47 
s0045_V4 0,18 0,73 0,52 0,65 0,64 0,76 0,14 0,71 s0045_V3 0,37 s0045_V3 0,48 
s0045_V5 0,05 0,09 0,36 0,43 0,69 0,49 0,04 0,54 s0045_V5 0,49 s0045_VZ 0,55 
s0045_V6 0,01 0,00 0,28 0,18 0,68 0,14 0,01 0,38 s0045_aV
R 
0,52 s0045_L1 0,58 
s0045_VX 0,09 0,18 0,37 0,49 0,89 0,62 0,09 0,67 s0045_L3 0,60 s0045_V4 0,64 
s0045_VY 0,01 0,00 0,19 0,28 0,26 0,00 0,02 0,24 s0045_VX 0,62 s0045_V6 0,68 
s0045_VZ 0,03 0,02 0,34 0,28 0,55 0,64 0,04 0,49 s0045_VZ 0,64 s0045_V5 0,69 
s0045_aVF 0,05 0,14 0,38 0,41 0,30 0,36 0,06 0,38 s0045_aVL 0,70 s0045_aV
R 
0,73 
s0045_aVL 0,07 0,03 0,36 0,58 0,47 0,70 0,11 0,58 s0045_L1 0,72 s0045_L2 0,73 
s0045_aVR 0,09 0,09 0,36 0,39 0,73 0,52 0,10 0,55 s0045_V4 0,76 s0045_VX 0,89 
     0,52 0,42     0,67  0,73 
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VIII - Similarity Measurements between different patients with different diagnosis - III 
 
 
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
 
Média total 
 
CC 
 
WT 
s0227_L1 0,17 0,25 0,42 0,63 0,32 0,77 0,17 0,606  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,483 
s0227_V1 0,30 s0227_VY 0,13 
s0227_L2 0,06 0,04 0,36 0,23 0,32 0,55 0,06 0,303 s0227_VY 0,43 s0227_aVF 0,18 
s0227_L3 0,07 0,10 0,26 0,48 0,20 0,67 0,07 0,471 s0227_V6 0,44 s0227_L3 0,20 
s0227_V1 0,03 0,00 0,15 0,39 0,22 0,30 0,04 0,304 s0227_L2 0,55 s0227_aVL 0,22 
s0227_V2 0,08 0,02 0,32 0,47 0,32 0,60 0,07 0,466 s0227_V2 0,60 s0227_V1 0,22 
s0227_V3 0,13 0,09 0,34 0,59 0,35 0,74 0,12 0,563 s0227_aVF 0,61 s0227_VX 0,27 
s0227_V4 0,13 0,19 0,46 0,54 0,39 0,83 0,12 0,610 s0227_L3 0,67 s0227_V6 0,27 
s0227_V5 0,07 0,03 0,26 0,47 0,35 0,80 0,07 0,541 s0227_aVR 0,70 s0227_L2 0,32 
s0227_V6 0,05 0,01 0,25 0,35 0,27 0,44 0,05 0,355 s0227_VX 0,70 s0227_V2 0,32 
s0227_VX 0,07 0,06 0,27 0,43 0,27 0,70 0,08 0,464 s0227_aVL 0,73 s0227_L1 0,32 
s0227_VY 0,04 0,00 0,31 0,35 0,13 0,43 0,05 0,365 s0227_V3 0,74 s0227_V3 0,35 
s0227_VZ 0,16 0,10 0,46 0,69 0,49 0,84 0,15 0,673 s0227_L1 0,77 s0227_V5 0,35 
s0227_aVF 0,06 0,02 0,28 0,35 0,18 0,61 0,07 0,416 s0227_V5 0,80 s0227_V4 0,39 
s0227_aVL 0,10 0,14 0,32 0,57 0,22 0,73 0,10 0,541 s0227_V4 0,83 s0227_VZ 0,49 
s0227_aVR 0,09 0,10 0,39 0,35 0,61 0,70 0,10 0,567 s0227_VZ 0,84 s0227_aVR 0,61 
     0,31 0,65     0,79  0,42 
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IX - Similarity Measurements between a patient and a healthy control - I 
  
 
ED 
 
 
DTW 
 
 
Mi 
 
 
Mah 
 
 
WT 
 
 
CC 
 
 
DCT 
 
Média (3 
melhores 
métodos) 
 
Média 
total 
 
 
CC 
 
 
WT 
s0462_L1 0,12 0,11 0,34 0,56 0,28 0,68 0,11 0,51  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,41 
s0462_L2 0,00 s0462_L3 0,10 
s0462_L2 0,02 0,00 0,24 0,11 0,56 0,00 0,02 0,30 s0462_L3 0,00 s0462_aVL 0,12 
s0462_L3 0,00 0,00 0,10 0,14 0,10 0,00 0,01 0,11 s0462_V6 0,00 s0462_VY 0,17 
s0462_V1 0,02 0,00 0,17 0,34 0,28 0,24 0,03 0,28 s0462_VY 0,00 s0462_aVF 0,17 
s0462_V2 0,09 0,30 0,45 0,57 0,52 0,70 0,08 0,60 s0462_aVF 0,00 s0462_V1 0,28 
s0462_V3 0,09 0,19 0,48 0,52 0,74 0,81 0,06 0,69 s0462_V5 0,10 s0462_L1 0,28 
s0462_V4 0,05 0,01 0,35 0,29 0,99 0,65 0,05 0,66 s0462_V1 0,24 s0462_aVR 0,47 
s0462_V5 0,01 0,00 0,17 0,10 0,97 0,10 0,01 0,41 s0462_aVR 0,32 s0462_V2 0,52 
s0462_V6 0,00 0,00 0,15 0,08 0,89 0,00 0,00 0,37 s0462_aVL 0,49 s0462_L2 0,56 
s0462_VX 0,05 0,01 0,31 0,32 0,84 0,52 0,04 0,56 s0462_VX 0,52 s0462_VZ 0,57 
s0462_VY 0,00 0,00 0,14 0,18 0,17 0,00 0,01 0,16 s0462_VZ 0,59 s0462_V3 0,74 
s0462_VZ 0,07 0,04 0,41 0,47 0,57 0,59 0,08 0,54 s0462_V4 0,64 s0462_VX 0,84 
s0462_aVF 0,01 0,00 0,13 0,10 0,17 0,00 0,01 0,13 s0462_L1 0,68 s0462_V6 0,89 
s0462_aVL 0,03 0,00 0,25 0,41 0,12 0,49 0,04 0,38 s0462_V2 0,70 s0462_V5 0,97 
s0462_aVR 0,07 0,03 0,38 0,29 0,47 0,32 0,08 0,39 s0462_V3 0,81 s0462_V4 0,99 
     0,51 0,34     0,66  0,83 
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X - Similarity Measurements between a patient and a healthy control - II 
 
 
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média 
total 
 
CC 
 
WT 
s0303_L1 0,07 0,19 0,33 0,41 0,38 0,57 0,07 0,45  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,35 
s0303_L2 0,00 s0303_L3 0,07 
s0303_L2 0,01 0,00 0,16 0,04 0,89 0,00 0,01 0,36 s0303_L3 0,00 s0303_aVF 0,10 
s0303_L3 0,01 0,01 0,14 0,15 0,07 0,00 0,02 0,12 s0303_VY 0,00 s0303_VY 0,13 
s0303_V1 0,02 0,00 0,23 0,25 0,21 0,26 0,02 0,25 s0303_aVF 0,00 s0303_aVL 0,17 
s0303_V2 0,02 0,01 0,30 0,26 0,25 0,32 0,03 0,29 s0303_V6 0,11 s0303_V1 0,21 
s0303_V3 0,04 0,17 0,35 0,36 0,33 0,60 0,05 0,44 s0303_aVR 0,23 s0303_V2 0,25 
s0303_V4 0,07 0,12 0,44 0,37 0,43 0,76 0,06 0,54 s0303_V1 0,26 s0303_V3 0,33 
s0303_V5 0,01 0,00 0,18 0,06 0,76 0,37 0,00 0,34 s0303_V2 0,32 s0303_VZ 0,37 
s0303_V6 0,00 0,00 0,18 0,06 0,50 0,11 0,00 0,25 s0303_V5 0,37 s0303_L1 0,38 
s0303_VX 0,08 0,19 0,34 0,46 0,73 0,57 0,08 0,59 s0303_aVL 0,47 s0303_V4 0,43 
s0303_VY 0,00 0,00 0,20 0,19 0,13 0,00 0,01 0,17 s0303_L1 0,57 s0303_V6 0,50 
s0303_VZ 0,05 0,03 0,36 0,42 0,37 0,76 0,06 0,52 s0303_VX 0,57 s0303_VX 0,73 
s0303_aVF 0,00 0,01 0,13 0,08 0,10 0,00 0,01 0,10 s0303_V3 0,60 s0303_V5 0,76 
s0303_aVL 0,02 0,03 0,28 0,35 0,17 0,47 0,02 0,37 s0303_V4 0,76 s0303_aVR 0,87 
s0303_aVR 0,03 0,00 0,33 0,11 0,87 0,23 0,03 0,48 s0303_VZ 0,76 s0303_L2 0,89 
     0,41 0,33     0,62  0,70 
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XI - Similarity Measurements between a patient and a healthy control - III 
  
ED 
 
DTW 
 
Mi 
 
Mah 
 
WT 
 
CC 
 
DCT 
Média (3 
melhores 
métodos) 
Média 
total 
 
CC 
 
WT 
s0311_L1 0,10 0,22 0,36 0,50 0,84 0,67 0,11 0,67  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0,51 
s0311_VY 0,00 s0311_VY 0,16 
s0311_L2 0,03 0,05 0,22 0,13 0,72 0,07 0,03 0,36 s0311_L2 0,07 s0311_aVF 0,24 
s0311_L3 0,06 0,04 0,35 0,53 0,30 0,66 0,07 0,51 s0311_V6 0,08 s0311_V1 0,29 
s0311_V1 0,03 0,00 0,18 0,36 0,29 0,39 0,04 0,34 s0311_V4 0,21 s0311_L3 0,30 
s0311_V2 0,11 0,04 0,49 0,62 0,73 0,75 0,10 0,70 s0311_V5 0,37 s0311_V6 0,33 
s0311_V3 0,19 0,27 0,59 0,74 0,92 0,86 0,12 0,84 s0311_V1 0,39 s0311_VZ 0,50 
s0311_V4 0,21 0,65 0,52 0,72 0,95 0,21 0,16 0,77 s0311_aVF 0,43 s0311_VX 0,52 
s0311_V5 0,04 0,01 0,24 0,32 0,95 0,37 0,03 0,55 s0311_aVR 0,47 s0311_aVL 0,52 
s0311_V6 0,01 0,00 0,20 0,13 0,33 0,08 0,01 0,22 s0311_VX 0,56 s0311_L2 0,72 
s0311_VX 0,02 0,00 0,20 0,16 0,52 0,56 0,02 0,42 s0311_L3 0,66 s0311_V2 0,73 
s0311_VY 0,00 0,00 0,12 0,16 0,16 0,00 0,01 0,15 s0311_L1 0,67 s0311_L1 0,84 
s0311_VZ 0,16 0,15 0,45 0,71 0,50 0,86 0,12 0,69 s0311_aVL 0,68 s0311_V3 0,92 
s0311_aVF 0,03 0,01 0,27 0,28 0,24 0,43 0,04 0,33 s0311_V2 0,75 s0311_aVR 0,95 
s0311_aVL 0,07 0,14 0,37 0,57 0,52 0,68 0,08 0,59 s0311_V3 0,86 s0311_V4 0,95 
s0311_aVR 0,07 0,05 0,31 0,25 0,95 0,47 0,07 0,57 s0311_VZ 0,86 s0311_V5 0,95 
     0,59 0,47     0,75  0,89 
 
 
